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Abstract 
 
Sphingolipids (SLs) are minor cell membrane amphyphilic components, residing in the 
external layer of the plasma membrane (PM), with the hydrophobic moiety, the ceramide 
(Cer), inserted into the membrane layer and the hydrophilic head group protruding toward 
the extracellular environment. They are a family of several compounds with different 
structural properties: the phospholipid, sphingomyelin (SM), the glycosphingolipids (GSLs) 
characterized for containing a complex oligosaccharide chain as hydrophilic moiety and 
gangliosides, GSLs containing sialic acid. As membrane components, SLs participate to 
modulate several cell processes, such as  cell growth, differentiation, morphogenesis, cell 
to matrix interaction and cell to cell communication. From this, it follows that a defect in SL 
metabolism can obviously lead to a great number of dysfunctions, ranging from 
neurodegeneration to cancer. 
Along my Ph.D. course I considered the different faces of SLs roles:  from their involvement 
in physiology to that in pathology. 
 
i.Sphingolipids and health. 
SLs cluster to form SL-enriched domains on cellular PM (lipid rafts, caveolae, and 
glycosynapses) providing a microenvironment within the PM for reciprocal interaction 
between lipids and proteins. In particular biochemical analyses have demonstrated that 
GSLs-enriched microdomains contain several transducer molecules, especially membrane-
anchored signal transduction molecules, such as tyrosine kinases belonging to the Src 
family. Although it has been speculated that GSLs are involved in cell differentiation, 
proliferation and functions such as phagocytosing, there are quite few evidence that GSLs, 
by themselves, directly mediate signal transduction, which lead to these cell functions. 
Lactosylceramide-enriched microdomain in neutrophils Lactosylceramide 
(LacCer), a neutral GSL, is abundantly expressed on human neutrophils, and specifically 
recognizes several pathogenic microorganisms. It has been previously demonstrated that 
LacCer forms PM lipid domains, that can be separated by detergent treatment of cells 
followed by ultracentrifugation, and that these lipid domains are coupled with Lyn, a Src 
family kinase. Ligand binding to LacCer activates Lyn, resulting in neutrophils functions, 
such as superoxide generation, phagocytosis and migration. The presence of LacCer 
molecular species with Cer containing a very long fatty acid chain is necessary for the 
association of Lyn with LacCer-enriched PM domains and LacCer-mediated functions. Lyn is 
associated by a palmitoyl anchor to the cytoplasmic leaflet, while LacCer is inserted into the 
outer layer of membrane bilayer. So the question is: how does LacCer interact with signal 
transducer molecules?  
The GSL-protein interactions in neutrophilis have been investigated by photoactivable GSLs. 
These molecules have been administered and taken up by the cell PM. When cells  are 
illuminated, the photoactivable group, linked to the terminal portion of Cer, yields a very 
reactive intermediate, that covalently binds  the molecules in the close environment.  
For the first time, at the best of our knowledge, we show a direct connection, across the 
PM, between GSLs and palmitoylated proteins: these results suggest that LacCer with a 
long fatty acid chain in Cer moiety could be the key-player of the transduction of 
information across the PM, modulating membrane interdigitation, through the long acyl 
chain, and forming specific PM microdomains.  
 
ii. Sphingolipids and diseases. 
Implication in neurodegenerative disorders 
SLs are particularly abundant in the nervous system where they play crucial roles regulating 
signaling events. Severe neurodegeneration is the prominent pathological hallmark of the 
most sphingolipidoses, inherited metabolic diseases characterized by a defect in the 
lysosomal GSL catabolism. Most of sphingolipidosis are caused by deficiencies of a specific 
lysosomal hydrolases, resulting in the accumulation of undegraded lipid metabolite in many 
cells.  
Secondary accumulations of gangliosides: the case of Niemann-Pick type A 
Niemann-Pick Disease (NPD) is a rare, autosomal recessive, lysosomal storage disease 
resulting from a deficiency in acid sphingomyelinase (ASM) activity. If ASM is absent or not 
functioning properly, SM cannot be metabolized properly and is accumulated within the 
cell, eventually causing cell death and the malfunction of major organ systems. In NPD type 
A, residual enzyme activity is very low (<5%)  and in NPD-A patients, storage pathology is 
severe within neurons and glial cells throughout the nervous system resulting in 
progressive, global deterioration of neurological function and death by 3 years of age.  
To better understand the secondary biochemical mechanism underling the pathogenesis 
and the importance of these secondary alterations of SL metabolism on lysosomal diseases, 
we analyzed lipid composition of CNS and extraneural tissues from the acid 
sphingomyelinase-deficient (ASMKO) mouse, the animal model of NPD type A, that has 
been developed using gene targeting and embryo transfer techniques. Our data show an 
unexpected  tissue specific selection of the accumulated molecular species of SM, and an 
accumulation of GM3 and GM2 gangliosides in both neural and extraneural tissues, that 
cannot be solely explained by the lack of ASM.  In ASMKO mice, we observed the 
preferential accumulation of SM molecular species with shorter acyl chains in the nervous 
system, but not in extraneural tissues. The unbalance toward C18/C16-fatty acid containing 
SM species was detectable as early as SM accumulation started, and monosialoganglioside 
accumulation followed immediately afterwards. These changes in SL patterns should thus 
represent the effect of secondary biochemical pathways altered as a consequence of a non-
related primary cause. The mechanism underlying these changes still remains to be 
elucidated and is probably the result of changes in the expression and/or activity of more 
than one single enzyme, and of anomalies in the traffic of the substrate/product 
concentrations in multiple cellular compartments. Several pieces of evidence suggest that 
altered SL metabolism results in a non-physiological PM composition and organization, 
leading to altered PM-originated signalling pathways that could be relevant to the onset of 
cellular damage and of tissue pathology. 
Chaperone therapy for GM2 gangliosidosis: Pyrimethamine and Sandhoff 
Disease Sandhoff disease is an autosomal recessive neurodegenerative disease 
characterized by the intralysosomal accumulation of GM2 ganglioside. This is due to 
mutations in the β-hexosaminidases β-chain gene, resulting in a β-hexosaminidases A (αβ) 
and B (ββ) deficiency. Lysosomal enzymes are synthesized in the endoplasmic reticulum 
(ER), and most of them are transported to the Golgi apparatus for glycosylation and 
taggeting for lysosomes, by the addition of mannose-6-phosphate. The ER contains a highly 
conserved degradation pathway, to protect cells from misfolding and potentially toxic 
proteins. Thus, the protein turnover ensures integrity and biological functions of cells. 
Treatment of sphingolipidoses, such as Sandhoff disease, have received increasing interest 
despite the low incidence. However, the replacing enzyme therapy meets the problem to 
be ineffective over the blood brain barrier and thus new approaches are now under 
investigation. One of these is the use of pharmacological chaperones. Pyrimethamine, a 
drug used to treat or prevent serious parasite infections, such as toxoplasmosis and 
malaria, has been described to act as chaperone for the β-hexosaminidase. Fibroblasts from 
two cases of juvenile Sandhoff disease, displaying the new mutations C1082+5G>A (#1) and 
C446-13A>G (#2) in the HEX B gene, were treated with pyrimethamine. The two examined 
cell lines, after treatment with pyrimethamine, showed an increased total β-
hexosaminidase activity, so that the residual value was around 10%. This value should be 
enough to limit the accumulation of GM2. In contrast to this, cells treated with 
pyrimethamine and fed with isotopically tritium labeled ganglioside GM1 did not show any 
GM2 lysosomal catabolism. This negative result was explained after fractionation of the 
total cell proteins by ion exchange DEAE column chromatography. Clearly, we found that 
the increased β-hexosaminidase activity on the artificial substrate was due to the increase 
of the activity of β-hexosaminidase isoform S. Unlikely, the isoform S, even if it hydrolyzes 
the artificial compound, does not recognize the natural substrate GM2 and, therefore, the 
pyrimethamine is unable to modify cell lysosomal activity in the two cell lines showing the 
new mutations C1082+5G>A and C446-13A>G, and, moreover, cannot be used as a 
therapeutic drug for the these two patients. Our results are in agreement with a previous 
information on the selective activity of pyrimethamine depending on the mutation and 
confirm the advantages deriving from the use of patients’ fibroblasts for the decision on 
the use of pyrimethamine as therapeutic drug.  
Implication in cancer  
Tumor cells are characterized by aberrant glycosylation processes responsible to increase 
proliferation and motility. A precise content and molar ratio between SLs is necessary in 
cells to have the correct membrane organization and the correct interaction processes 
between membrane components and membranes of adjacent cells.  
Cell surface glycohydrolase modulation during tumor irradiation. Radiotherapy 
has actually been used clinically for a number of years, with very positive results on tumor 
reduction. Irradiation of cancer cells leads to cell death by different mechanism. DNA 
damage, mitochondrial damage and oxidative stress bring mainly to necrosis, whereas the 
PM production of ceramide leads to apoptosis. The ceramide mediated apoptosis has been 
reported to depend on activation of cell surface sphingomyelinase and the following 
activation of the ceramide dependent phosphorylation cascade. Other enzymes of the SL 
metabolism have been recently found associated to the external leaflet of the PMs, like the 
α-sialidase, the β-hexosaminidase, the β-galactosidase and the β-glucosidase. These 
glycohydrolases lead to ceramide from complex GSLs and suggest a new way to trigger the 
ceramide-induced apoptosis. The PM enzymatic activities display optimal pH under mild 
acidic condition. This is found in specific membrane domains, known as lipid rafts, where 
GSLs are highly enriched together with ion exchanger proteins such as proton pumps.  
Human breast cancer cell line T47D was studied in detail. In these cells the increase of 
activity of β-glucosidase and β-galactosidase was parallel to the increase of irradiation dose 
up to 60 Gy and continued with time, at least up to 72 hr from irradiation. β-glucosidase 
increased up to 17 times and β-galactosidase up to 40 times with respect to control. 
Sialidase Neu3 and sphingomyelinase increased about 2 times at a dose of 20 Gy but no 
further significant differences were observed with increase of radiation dose and time. 
After irradiation, we observed a reduction of cell proliferation, an increase of apoptotic cell 
death and an increase of PM ceramide up to 3 times, with respect to control cells. Tritiated  
GM3 ganglioside has been administered to T47D cells under conditions that prevented the 
lysosomal catabolism. GM3 became component of the PMs and was transformed into 
LacCer, GlcCer and ceramide. The quantity of ceramide produced in irradiated cells was 
about two times that of control cells.  
We are characterizing the role of PM glycohydrolases in the process of apoptosis activated  
by cell irradiation and developing new protocols for radiation therapy combined with 
pharmacological treatments capable to exert enhanced antitumor activity through synergic 
action. Increase of the activities of the PM glycohydrolases, and of the apoptotic process, 
cold be obtained by i) activating with specific drugs the PM proton pumps to decrease the 
local extracellular pH; ii) the use of recombinant glycohydrolases; iii) using drugs or 
chaperones capable to modulate directly the glycohydrolase activities. Concerning this last 
opportunity, molecules acting as chaperones able to up-regulate the activity of lysosomal 
enzymes are known. Also if no information is available, considering the nature of PM 
enzymes, we believe that these regulators should be effective also on PM enzymes.  
  
  
 
 
 
 
 
Index 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABBREVIATIONS  pag. 10 
  
STATE of THE ART  pag. 13 
REFERENCES                 pag. 22 
  
Theme I:  
“Role of Lactosylceramide eriched lipid domains in activation processes of neutrophils”    pag. 27 
INTRODUCTION                                                                                                                                                      pag. 28 
AIM                                                                                                                                                                            pag. 37 
MATHERIALS and METHODS                                                                                                                             pag. 42 
RESULTS                                                                                                                                                                   pag. 46 
DISCUSSION                                                                                                                                                            pag. 53 
REFERENCES                                                                                                                                                           pag. 56 
  
Theme II  
“Are secondary accumulation of gangliosides the triggering factor for Sphingolipidosis? The 
case of Niemman Pick type A”                                                                                                                                            pag. 61 
INTRODUCTION                                                                                                                                                      pag. 62 
AIM                                                                                                                                                                            pag. 70 
MATHERIALS and METHODS                                                                                                                             pag. 72 
RESULTS                                                                                                                                                                   pag. 75 
DISCUSSION                                                                                                                                                            pag. 86 
REFERENCES                                                                                                                                                           pag. 90 
  
Theme III  
“Chaperone therapy for the treatment of GM2 gangliosidosis:  Pyrimethamine and Sandhoff 
Disease”                                                                                                             pag. 97 
INTRODUCTION                                                                                                                                                      pag. 98 
AIM                                                                                                                                                                            pag. 107 
MATHERIALS and METHODS                                                                                                                             pag. 109 
RESULTS                                                                                                                                                                   pag. 113 
DISCUSSION                                                                                                                                                            pag. 120 
REFERENCES                                                                                                                                                           pag. 123 
  
Theme IV:  
“Cell surface sphingolipid glycohydrolases modulation during tumor irradiation”                          pag. 128 
INTRODUCTION                                                                                                                                                      pag. 129 
AIM                                                                                                                                                                            pag. 141 
MATHERIALS and METHODS                                                                                                                             pag. 143 
RESULTS                                                                                                                                                                   pag. 149 
DISCUSSION                                                                                                                                                            pag. 156 
REFERENCES                                                                                                                                                           pag. 160 
  
  
  
 
 
 
  
 
 
 
 
 
Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
AMP-DNM N-(5-adamantane-1-yl-methoxy)pentyldeoxynojirimycin 
BME  Basal Modified Eagle’s Mediumù 
CBE  Conduritol B Epoxide 
Cer  Ceramide 
CNS                      Central Nervous System 
CTRL                    Control 
DMEM  Dulbecco Modified Eagle’s Medium 
DMSO                 Dimethyl sulfoxide 
D-HL-60              DMSO-treated neutrophilic differentiated human promyelocytic leukemia 
DRM                    Detergent Resistant Membrane 
EIPA  5-(N-Ethyl-N-isopropyl)amiloride 
ER                         Endoplasmatic Reticulum 
ERAD                   Endoplasmatic Reticulum Associated Degradation 
ERT                      Enzyme Replacement Terapy 
ETT                       Enzyme Target Terapy 
FBS   Fetal bovine serum 
GalCer                 Galactosyl ceramide 
GBA2  Non-lysosomal β-glucosylceramidase 
GD                        Gaucher Diseases 
GlcCer  Glucosyl ceramide 
GSL  Glycosphingolipid 
HD                        High Density 
HL-60                  Human promyelocytic leukemia 
HPTLC  High performance thin layer chromatography 
HPLC                   High performance liquid chromatography 
KO                        Knock out 
LacCer  Lactosyl ceramide 
LSD                      Lysosomal Storage Disease 
MEM  Minimum Essential Medium with Earle’s Salt 
MUB  4-Methylumbelliferone 
MUB-Gal 4-Methylumbelliferyl--D-galactopyranoside 
MUB-Glc 4-Methylumbelliferyl--D-glucopyranoside  
MUG  4-Methylumbelliferyl--N-acetylglucosaminide 
MUGS  4- Methylumbelliferyl--N-acetylglucosaminide-6-sulphate 
Neu3  PM associated sialidase 
NPD                     Niemann Pick Disease 
PAGE                Polyacrylamide gel electrophoresis 
PAMPS                Pathogen-associated molecular patterns 
PBS  Phosphate buffered saline 
PC                         Pharmacological Chaperone 
PM  Plasma membrane 
PNS                      Post Nuclear Supernatant 
PRR                      Pattern recognition receptor 
PVDF  Polyvinylidene di fluoride 
SD                        Sandhoff Disease 
SL                         Sphingolipid 
SM  Sphingomyelin 
SMase  Sphingomyelinase 
SRT                      Substrate Reduction Terapy 
ST-1  GM3 synthase, CMP-NeuAc: LacCer α2-3 sialyltransferase 
ST-II  GD3 synthase, CMP-NeuAc: GM3 α2-8 sialyltransferase 
ST-IV  CMPNeuAc: GA1/GM1/GD1b/GT1c α2-3 sialyltransferase 
WT                       Wild-type 
β-Gal  β-galactosidase 
β-GlC  β-glucosidase 
β-Hex  β-hexosaminidase 
 
 
Ganglioside nomenclature is in accordance with IUPAC-IUBMB recommendations (IUPAC-IUBMB 
1998) 
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SPHINGOLIPIDS 
Sphingolipids (SLs) are minor cell components, residing in the external layer of the plasma 
membrane (PM) [1] consisting in a hydrophobic moiety, ceramide, and in a hydrophilic headgroup. 
The ceramide (Cer) is responsible for the insertion into the outer layer of the PM, with the 
hydrophilic headgroup protruding in the extracellular environment.  
Cer itself is also a SL, the most simple SL, and its structure is that of a long chain amino alcohol like 
the 2-amino-1,3-dihydroxyoctadec-4-ene (sphingosine), connected to a fatty acid by an amide 
linkage. Of the four possible configuration of sphingosine, only the 2S,3R is present in nature [2,3]. 
Cer is the common precursor of complex SLs, which are synthesized by addition of polar 
molecules to hydroxyl group in position 1 of the sphingoid base [4].  
Hundreds of SL molecular species, differing in their polar head group, sphingoid base and fatty 
acyl moiety, have been described. Referring to the polar head group there is the phosphocholine, 
component of sphingomyelin (SM), and a very wide group of oligosaccharide chains, components 
of glycosphingolipids (GSLs) [5]. GSLs containing one or more sialic acid residues in the 
carbohydrate chain are referred to as gangliosides. Based on the sequences of the core 
carbohydrate residues, GSLs are classified into a number of series (including gala-, ganglio-, 
isoganglio-, lacto-, neolacto-, lactoganglio-, globo-, isoglobo-, and muco-series). Structural 
diversity in their carbohydrate chains is a hallmark of GSLs. At present, 172 neutral GSLs, 24 
sulfated GSLs, and 188 gangliosides with variations in the carbohydrate chain have been reported 
in a variety of vertebrate tissues and organs [6]. This complexity is increased many fold when 
heterogeneity in the lipophilic components is taken into consideration. 
The glycolipids are clearly significant contributors to the structure of the outer leaflet of most 
eukaryotic cell membranes. The molar ratio of these molecules relative to the other major 
membrane lipids (phospholipids, cholesterol and glycerolipids) varies from being <0.5% in 
erythrocytes to about 6% in neurons. Thus, in neurons SL are about 12% of total lipids of external 
PM layer. 
Variations in type, number, linkage and further modification of sugar and sialic acid residues 
within the oligosaccharide chain but also the different composition of the lipid moiety give rise to 
a combinatorial variety of naturally occurring GSLs. 
 
BIOSYNTHESIS 
Glycolipid biosynthesis in animals requires the intracellular formation of the membrane anchor [7] 
and the subsequent addition of single carbohydrate residues [8]. Both events are coupled to 
intracellular movement of metabolic intermediates and final association of products to the PM 
                                                                                                                             
 
[9]. The combinatorial variety of naturally occurring 
combination of glycosyltransferase activities found in different species and cell types.
 
Ceramide 
The de novo biosynthetic pathway of SLs starts at the cytosolic face of the endoplasmic reticulum 
(ER), where enzyme activities responsible for the reaction sequence leading to 
Cer are localized. Cer synthesis (Figure 1
serine palmitoyl-transferase,
palmitoyl coenzyme A and in  less extent stearoy
In the following NADPH-dependent reaction, 3
sphinganine by 3-ketosphinganine reductase 
dihydroceramide by a N-acyltransferase 
desaturated to Cer in the dihy
 
Fig. 1 De novo ceramide biosynthesis
                                                                
GSLs can be largely attributed the 
) is due to the condensation, catalysed by the enzyme 
 of the amino acid L-serine with a fatty acyl coenzyme A, usually 
l coenzyme A, to give 3-ketosphinganine 
-ketosphinganine is reduced to D
[13]. Sphinganine is subsequently acylated to 
[14-16]. The major part of the dihydroceramide pool is 
droceramide desaturase reaction [17-19].  
. 
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the formation of 
[10-12]. 
-erythro-
 
                                                                                                                             
 
Cer is also generated during the catabolism of SLs that occurs in lysosomes, and rapidly converted 
to sphingosine which is largely r
and sphinganine with similar efficiency 
sphingosine produced by the catabolism of com
Cer can be also produced by the hydrolysis of SM and GSL catalyzed by 
PM [23,24].  
 
 
 
 
Fig. 2 Ceramide from catabolism
 
 
 
 
 
                                                                
ecycled. Cer synthase is able to use as substrate both sphingosine 
[20-22], so Cer can be also formed by 
plex SLs  (Figure 2).  
enzymes associated to the 
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Sphingomyelin and Sphingolipids  
The neo-synthesized Cer reaches directly the PM or it is used as common precursor in the GSLs 
and SM biosynthesis. In both cases the Cer reaches the Golgi apparatus by a not well defined 
mechanism [9], capable to address the synthesis of SM or GSL. Synthesis of SM occurs via 
addition of phosphocholine group to the hydroxyl group in position 1 of the sphingoid base of the 
Cer. In the case of the biosynthesis of GSLs, different membrane-bound glycosyltransferases are 
responsible for the sequential addition of sugar residues to the hydroxyl group in position 1 of the 
Cer, leading to the growth of the oligosaccharide chain.  
Glucosylceramide (GlcCer) is the first glycosylated product, formed by a Cer glucosyltransferase 
activity localized at the cytosolic side of the early Golgi membrane [25]. GlcCer can either directly 
reach the PM [26], presumably transported in a non-vesicular way [26], or be translocated to the 
luminal side of the Golgi, where it is further glycosylated by other glycosyltransferases located in 
this cellular district to generate more complex GSLs. Lactosylceramide(LacCer), the common 
precursor for the GSL series found in vertebrates, is formed by the addition of a galactose moiety 
from UDP-Gal to GlcCer catalysed by galactosyltransferase. The enzyme has been purified and 
cloned from rat brain [27]. LacCer formation and also the reactions leading to higher glycosylated 
lipids occur on the luminal leaflet of Golgi membranes [28]. Neo-synthesized GSLs move through 
the Golgi apparatus to the PM following the mainstream exocytotic vesicular traffic.  
 
Complex gangliosides  
A GSL series that is especially abundant on neuronal cells is the ganglio series. The biosynthesis of 
sialic acid-containing GSLs of this series, the gangliosides, is catalysed by glycosyltransferases in 
the lumen of the Golgi apparatus [8, 29, 30]. Gangliosides are structurally and biosynthetically 
derived from LacCer. LacCer and the gangliosides GM3, GD3 and GT3, serve as precursors for 
complex gangliosides of the o-, a-, b- and c-series (Figure 3). In adult human tissues, gangliosides 
from the o- and c-series are found only in trace amounts. The transferases that catalyse the first 
steps in ganglioside biosynthesis show high specificity towards their glycolipid substrates, i.e. for 
the formation of LacCer, GM3 and GD3. The relative amount of these GSLs in the steady state 
seems to determine the amount of o-series GSLs, which are derived only from LacCer, a-series 
gangliosides which are only derived from ganglioside GM3, and b-series gangliosides which are 
only derived from ganglioside GD3. Sialyltransferases I and II are much more specific for their 
glycolipid substrates than sialyltransferases IV and V, or than galactosyltransferase-II and GalNAc 
transferase. It was assumed that different transferases catalyse the formation of homologous 
gangliosides of different series.  
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Fig. 3 Scheme of Ganglioside biosynthesis. “G” denotes “ganglioside;” “A” denotes “asialo” or lacking 
sialic acid; “M” denotes “monosicalo,” “D” denotes “disialo;” numbers denote carbohydrate sequence. 
Cer: ceramide; GlcCer: glucosylceramide; LacCer: lactosylceramide; GalNac: N-acetylgalactosamine. 
(Adapted from [31]). 
 
CATABOLISM 
Another important point of regulation of PM SLs composition is the lipidic degradation that 
occurs in the acidic compartments of the cells, the lysosomes, where SLs are transported by the 
endocytic vesicular flow through the early and late endosomal compartment to be catabolyzed. 
Lysosomal glycosidases sequentially cleave off the sugar residues from the non-reducing end of 
their glycolipid substrates. The resulting monosaccharides, sialic acids, fatty acids and sphingoid 
bases can leave the lysosome and be used within recovery processes or can be further degraded. 
The intralysosomal degradation of most, if not all, GSLs requires, besides exoglycohydrolases, 
effector protein molecules named “sphingolipid activator proteins (SAPs, or saposines)” [32] . 
The sequence of sugar removal from gangliosides within the lysosomes is as follows: from GM1, 
galactose is then removed by a β-galactosidase, working in the presence of either the GM2-AP or 
SAP-B [33], to produce GM2. The resulting ganglioside GM2 is cleaved to ganglioside GM3 and N-
acetyl-galactosamine only by the β-hexosaminidase isoenzymes Hex A which requires the GM2-
AP, an activator that is essential for the in vivo degradation of the GM2 gangliosides. 
In some cells and animals, sialic acid is removed from GM1 and GM2 by a specific sialidase (GM1- 
and GM2- sialidase) producing the corresponding a-sialo derivatives GA1 and GA2, that, by the 
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action of β-galactosidase and β-hexosaminidase or only β-hexosaminidase respectively, are 
converted to LacCer.  
LacCer is produced also directly from GM3 by the action of a sialidase which cleaves this 
ganglioside into LacCer and sialic acid in a reaction stimulated by SAP-B [34]. LacCer is then 
degraded to Cer by the sequential action of a β-galactosidase (in the presence of either SAP-B or –
C) and β-glucosidase [35] (which is a glucosidase enzyme which acts upon -1,4 bonds linking two 
glucose). 
Cer is cleaved by acid ceramidase in the presence of SAP-D [36] into sphingosine and a fatty acid. 
Together with the other cleavage products, these two metabolites are able to leave the 
lysosome. An alternative pathway for ganglioside/GSLs degradation is the splitting of the β-
glucosidic linkage between glucose and Cer, with the formation of Cer and the oligosaccharide. 
The enzymes catalysing this reaction, named “endoglycoceramidases” or “Cer glycanases” [37-
42] appear to require, or to be markedly activated, by specific activator proteins whose action 
would be essential under in vivo conditions [37]. Endoglycoceramidases have been found to occur 
in some bacteria [37] and leeches [38]. Although described to occur in lactating mammary glands 
of rodents [40], the presence of this enzyme in vertebrate and, particularly, mammalian tissues is 
yet to be definitely assessed. 
For the non-glycosylated SLs, like Cer and SM, non-lysosomal degradation steps are known which 
apparently do not need the assistance of an activator protein. SM is cleaved to Cer and 
phosphorylcholine. Cer later on is degraded into sphingosine and a fatty acid by ceramidases. 
Sphingosine moves into the cytosol where it  can be phosphorylated to sphingosine-1-phosphate 
and further degraded to phosphoethanolamine and long chain aldehyde. But at the same time 
sphingosine-1-phosphate acts as metabolic regulator [32,43] 
Enzymes that are capable to remove the fatty acid moiety from several SLs (SM, gangliosides and 
some neutral GSLs) producing the corresponding lyso-derivatives were also described [43,44]. 
These enzymes, known as SL Cer N-deacylases, were detected in bacteria. No evidence was yet 
provided for their occurrence in vertebrates. However, it is known that in the brain of patients 
suffering from some sphingolipidoses where there is accumulation of lyso-GSLs [45], these 
accumulated compounds seems to be the products of proteins having this kind of enzymatic 
activity. These products can leave the organelle and re-enter the biosynthetic pathway or serve as 
energy sources and be further degraded. 
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BIOCHEMICAL ROLES OF SPHINGOLIPIDS 
SLs are a family of membrane lipids with important roles in the regulation of the membrane 
fluidity and membrane organization [1]. 
SL are amphiphilic molecules: they are characterized by a hydrophobic portion, embedded in the 
lipid core of biological membranes, and by a hydrophilic portion protruding in the extracellular 
milieu. The Cer backbone confers some physical-chemical properties to the SLs that differs from 
those of other membrane lipids. In fact, the amidic linkage, with the contemporary presence in 
the same molecule of a hydrogen bond donor and an acceptor group (the carbonyl oxygen and 
the amidic hydrogen), allows the formation of a network of hydrogen bonds. The presence of 
hydrogen linkages considerably stabilizes the SL segregation in specific membrane areas, which 
appear enriched with this lipid family and for this reason they have been defined “SL-rich 
membrane domains” [46,47]. In addition, the numerous hydrogen bonds in these domains confer 
rigidity and resistance to the membrane allowing their differentiation by physical-chemical 
properties from the remaining membrane. 
Recent results suggest new aspects of lipid function: not only structural component of cell 
membrane but also fundamental actors of signalling and regulatory pathways. 
Unexpectedly, advances in biochemical and molecular studies of SL metabolism and function 
during the past 2 decades revealed Cer, Cer-1-phosphate, GlcCer, LacCer, galactosylceramide 
(GalCer), sphingosine, sphingosine-1-phosphate (S1P) are not only precursors or catabolytes, but  
are biological active having key roles in the regulation of several fundamental biological processes 
(Figure 4) [46,47]. 
These molecules forming cell type specific profiles, have essential roles in several aspect of cell 
biology: 
 
• Cell growth 
• Differentiation 
• Morphogenesis 
• Cell to matrix interaction 
• Cell to cell communication 
 
Since SLs have many putative biological roles, it’s easy to think that a defect in their metabolism 
lead to a great number of biochemical dysfunctions, that consequently result in a several 
pathological manifestation from neurodegeneration to cancer. 
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In this Thesis, I report different aspects of SLs biochemistry, with particular interest in both the 
physiological and pathological SL processes,  with the aim to understand how perturbation of SLs 
metabolism can alter intracellular signalling pathways. 
 
 
 
 
 
Fig. 3 Sphingolipid functions. 
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THE LIPID RAFT CONCEPTS 
In the late 1980s, a diverse series of experimental findings collectively gave rise to the lipid 
domain hypothesis. Lipid domains were originally defined as membrane zones, i.e., ordered 
structures created as a consequence of the lateral segregation of sphingolipids (SLs) and differing 
from the surrounding membrane in their molecular composition and properties. This definition 
was subsequently modified to introduce the notion that membrane domains correspond to 
membrane areas stabilized by the presence of cholesterol within a liquid-ordered phase. During 
the past two decades, the concept of membrane domains has become extremely popular among 
cell biologists, and these structures have been suggested to be involved in a great variety of 
cellular functions and biological events [1,2,3]. 
The notion that different levels of order exist in biological membranes is deeply rooted in cellular 
biology. Cellular membranes are composed mainly of phospholipids, SLs, cholesterol, and several 
types of membrane associated protein. The first level of ordered organization is the creation of 
the lipid bilayer, a consequence of the aggregational properties of complex amphipathic 
membrane lipids. The lipid bilayer provides a physical boundary between the cellular and 
extracellular environments, and a scaffold for molecules and molecular complexes that physically 
and functionally link these two environments. The lipid bilayer is characterized by several basic 
properties that are relevant to its biological functions: the bilayer as a whole is a very stable 
structure, however it allows its components a certain degree of lateral motility. As a consequence 
of this fluidity, components of biological membranes can be arranged following a non-
homogenous lateral distribution, leading to the creation of membrane areas (“domains”) with a 
highly differentiated molecular composition and supermolecular architecture. The non-
homogeneous lateral distribution of membrane components is made possible by the existence of 
lateral interactions stabilizing different membrane domains, and creating a second level of order 
in the organization of biological membranes. Membrane microdomains are historically proposed 
to be lateral assemblies of specific lipids, in particular, cholesterol and SLs, involved in the sorting 
of proteins to the apical surface of polarized epithelial cells, and with which specific proteins 
interact [3-5]. 
 
Today different terms are used to define the membrane domains, as in the case of “caveolae”, 
membrane invaginations containing the protein caveolin [6] or “Lipid rafts” membrane domain 
that sort or transport proteins inside the cells. Others define membrane portions on the basis of 
chemico-physical or compositional features: DIM (detergent insoluble material) [7], DISAM 
(detergent-insoluble substrate attachment matrix) [7], DIG (detergent insoluble glycolipid-
enriched material) [8], DRM (detergent resistant membranes) [9], SEMF (SL enriched membrane 
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fraction) [10],  GEM, (glycolipid enriched membrane) [1]. Among all these definitions, the one that 
probably makes a better idea is “DRM”, because it relies on the biochemical characteristics that 
are used for the purification of lipid domains: they are relatively insolubly in nonionic detergent 
under specific experimental conditions and this is one of the most important characteristic of 
these domains from an experimental point of view (Figure 1), that allows us to separate the lipid 
rafts from the other part of cellular membrane.  
 
 
 
Fig. 1 Insolubility of lipid raft components in the presence of Triton X-100 and preparation of detergent-
resistant membranes (DRMs). Detergents in water solutions aggregate as small micelles over a critical 
micellar concentration (c.m.c.). The c.m.c. for Triton X-100 is 0.31 mM; at a 1% concentration many detergent 
monomers are therefore present in solution and enter into the fluid (“non-raft”) portions of the 
membrane. Fluid membranes containing Triton X-100 are dissolved and form small mixed micelles that are 
enriched in detergent, GPLs, and proteins. The detergent does not enter into the less fluid (“raft”) portions 
of membrane, which contain few proteins but are enriched in SLs and cholesterol. The membrane in these 
areas therefore maintains the bilayer structure. Detergent-resistant and detergent-soluble components can 
be separated by gradient centrifugation. The figure schematically depicts only the external membrane 
layer. Proteins are not illustrated, and the relative proportions of the membrane components as shown are 
not accurate. (Adapted from [3]). 
 
The great interest for lipid-rich membrane domains, that gave rise to the complex and 
controversial discipline of raftology in the last two decades, derived from the observation that 
some membrane-associated proteins are highly concentrated in these domains, even if the overall 
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protein content of these membrane areas in very low. It has been assumed that the trapping of 
certain proteins in lipid rafts might be somehow functional to their biological role [11]. Studies on 
model membranes, on detergent-resistant membrane fractions and in intact cells indicated, 
without doubt, that several classes of membrane-associated proteins display a strong preference 
for the association of lipid-rich membrane domains [12].  
Among most common raft-targeting motifs are the presence of GPI anchor or of a lipid 
modification (NH2 terminal myristoylation/palmitoylation and double palmitoylation), also 
transmembrane proteins are sometimes concentrated in lipid ratfs. Thus the presence of a lipid 
modifications or of a specific targeting sequence within the hydrophobic or the 
extracellular/cytoplasmatic domains is required. Finally peripheral proteins can be associated or 
recruited to lipid rafts, possibly indirectly via interaction with raft-resident proteins. 
Anyway it has been suggested and in some cases proven that the association with lipid-rich 
membrane domains, or with lipids within lipid domains, that can affect the functional properties 
of a membrane protein.  
 
Glycosphingolipids-ENRICHED MICRODOMAINS  
Glycosphingolipids (GSLs) cluster to forms GSL-enriched microdomains on cellular plasma 
membrane (PM), provide a microenvironment within the PM for reciprocal interactions between 
lipids and protein molecules participating in the control of signal transduction (Figure 2) [13].  
 
 
 
Fig. 2 Proposed structure and organization of a lipid raft microdomain in the PM. SLs, which include both 
SM  and GSLs, associate with cholesterol to form a more tightly packed domain. The regions rich in PC and 
other glycerol-based phospholipids are less densely packed, and form fluid regions outside the raft 
microdomains. Lipid rafts are enriched in GPI-anchored proteins and enzymes at their external surface, and 
acylated proteins, such as tyrosine kinases of the Src family  at the cytoplasmic surface. Transmembrane 
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integral proteins are generally excluded from rafts, and are found in the more fluid phospholipid-rich 
regions of the membrane [From http://www.uoguelph.ca/~fsharom/research/lipid.shtml]. 
 
The chemical structure of GSLs molecules makes them ideal in play the role of mediators of 
information transfer across the PM: the hydrophilic component is able to provide recognition 
sites and of interaction, while the hydrophobic portion allows it to interact with other 
components of the PM. 
There are a lot of evidence on the ability of GSLs to interact and modulate the activity of PM 
proteins, in some cases in a highly specific manner, such as receptor tyrosine kinase. This can be 
consider the starting step in the process of transferring the information across the membrane. 
But for some interaction between GSLs and proteins there is no information on how the process 
continues after the initial interaction: still remain to elucidate the molecular mechanism of such 
GSLs-proteins interactions [14-17]. 
The oligosaccharide chain of GSLs could interact with a membrane protein via i) aminoacid 
residues belonging to the intracellular loops of the protein, if the conformation of the 
polypeptide chian allows them to be sufficiently close to the membrane surface; ii) sugar residues 
in the glycans of a glycosylated protein, if the dynamics of the protein oligosaccharide chain 
allows the correct orientation toward the cell surface; iii) the hydrophilic portion to the anchor in 
the case of GPI-anchored proteins [18-21].  
Some evidence suggest that ceramide (Cer), the portion of the molecule that is insert into the 
outer layer and makes the GSLs to be a component of the membrane, could be involved in the 
intermediate steps of signalling process.  
The amide group of Cer is a rigid group, with a perpendicular orientation towards the two 
hydrocarbonyl chains, which parallel orientation stabilized by the presence of an unsaturation at 
position 4-5 of sphingosine. The hydroxyl group at position 2 of sphingosine, the amidic proton 
and the carbonyl oxygen, enable the Cer moiety to form hydrogen bonds, acting as hydrogen 
donors and acceptors. The orientation of the hydrogen bond donor and acceptor groups of SLs, is 
optimal to form lateral interactions and to considerably increase the stability in lipid-lipid 
interaction. This, together with a reduced GSL dynamics due to GSL-protein interactions, are very 
good requisites to promote the formation of rigid zones within the membrane. The Cer moiety 
contains a long chain base linked to a fatty acid chain. Sphingosine [(2S,3R,4E)-2-amino-1,3- 
dihydroxy-octadecene] is largely the main long chain base in mammals. However, the structure 
with 20 carbons is relatively abundant in neurons, where its content progressively increases along 
aging. This introduced the hypothesis of an involvement of C20-sphingosine containing GSLs in 
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functional processes. On the other hand, GSL’s Cer is heterogeneous concerning its fatty acid 
content [17, 22-26]. 
The thickness of a cellular membrane is related to the length of the hydrocarbonyl chains present 
in the membrane lipids. The maximum length of is determinate by the length of sphingosine 
belong to the water-lipid interface, so that, with the exception of less abundant Cer(s) containing 
very short fatty acids, it is the fatty acid structure that define the length of the whole Cer into the 
outer membrane layer [27,28].  
 
Lactosylceramide-ENRICHED MICRODOMAINS IN NEUTROPHILIS 
Although we are constantly exposed to infectious agents, we can generally resist these infections 
using the two immune systems: the innate and the adaptive immune systems. Even if the innate 
and adaptive immune systems both function to protect against microorganisms, they differ in a 
number of ways. The innate immune system is the inborn defense mechanism and the first line of 
defense against pathogenic organisms, such as bacteria, fungi, viruses, etc. Professional 
phagocytes, such as neutrophils and macrophages, are essential for the innate immunity system. 
Phagocytes express several specific receptors and adhesion molecules (pattern recognition 
receptors or PRRs) on their cell surface, including Toll-like receptors and β2 integrins, to recognize 
pathogen-associated molecular patterns (PAMPs) on microorganisms [29-32].  
Lactosylceramide (LacCer) is a neutral GSL, and is associated with a number of key cellular 
processes. It has been demonstrated that LacCer activates NADPH oxidase to modulate 
intercellular adhesion molecule-1 expression on human umbilical vein endothelial cells, and to 
induce the proliferation of human aortic smooth muscle cells. Therefore, it is possible that LacCer 
activates NADPH oxidase, and thereby affects the functions of superoxide producing cells. LacCer 
is also a receptor activator of NF-κB ligand and is essential for osteoclastogenesis mediated by 
macrophage colony stimulation factor. Recently, LacCer has been shown to recruit PCKα/ε and 
phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to 
endothelial cells and to regulate β1-integrin clustering and endocytosis on cell surfaces. LacCer 
has been shown to bind specifically to several types of pathogenic microorganism, including 
Escherichia coli, Bordetella pertussis, Bacillus dysenteriae, Propionibacterium freudenreichii, and 
Candida albicans, suggesting that LacCer plays roles in the interactions between these 
microorganisms and host cells [13,28,32-35]. 
Neutrophils play important roles in innate immunity. After infection  immediately migrate toward 
the infecting pathogen and phagocytose it via PRRs such as beta(2) integrin Mac-1(CD11b/CD18, 
CR3), CD14 and Dectin-1. In the second step, neutrophils kill the microorganisms with microbicidal 
molecules and through superoxide generation.  
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LacCer is the most abundant GSL in human neutrophils where accounts for about 70% of the GSL 
and it has been shown to bind specifically to several types of pathogenic microorganism. In 
addition, chemotactic and superoxide-generating activities are induced by addition of anti-LacCer 
monoclonal antibodies to cells. These immune cells migrate toward C. Albicans-derived β-glucan 
(CSBG), and generate superoxide anions via LacCer. Therefore, LacCer is thought to be involved in 
neutrophil microbicidal functions [33, 36]. 
We know that on neutrophil PM, LacCer forms lipid microdomanins with the Src family kinase Lyn, 
and serve as PRR responsible for several biological functions including chemotaxis, phagocitosis 
and superoxid generation. Anti-LacCer monoclonal antibody activates Lyn, which becomes 
phosphorylated, and it immunoprecipitates Lyn-associated domains from a detergent resistant 
membrane fraction prepared from cell membranes (Figure 3)[13,28,32-35]. 
 
 
 
Fig. 3 Role of neutrophils in innate immunity. The binding of microorganisms to LacCer induces clustering 
of LacCer enriched lipid domains, leading to superoxide generation and migration through Lyn-, PI3-k-, p38 
MAPK-, and protein kinase C-dependent signal transduction pathways (Adapted from [28]). 
 
Dimethyl sulfoxide (DMSO)-treated neutrophilic differentiated human promyelocytic leukemia 
HL-60 cells (D-HL-60 cells) possess chemotactic and superoxide-generating activities induced by 
formyl peptide fMLP. Interestingly, D-HL-60 cells do not show superoxide-generating or 
chemotactic activity induced by anti-LacCer antibodies, although these cells express almost the 
same amount of LacCer on the plasma membrane as neutrophils (Figure 4a and b). Moreover 
most of LacCer and Lyn, in both neutrophils and D-HL-60 cells, was recovered in DRM fraction. 
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 microdomains are 
g complex lipid species 
 these lipids participate in 
 same membrane areas. 
the membrane, allowing 
 cholesterol and the alkyl 
 parts. Interdigitation of 
 causing an association 
 of LacCer and Lyn. In 
 acid chain-contained 
 microdomains on the 
 acid chain-containing 
 (adapted from [35]). 
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The aims of this project was understand the real organization of LacCer
the objective to identificate 
neutrophilis.  
In particular the goal was to find 
enriched lipid rafts of D-HL-60 cells in order to elucidate the role of very long fatty acid chains in 
GSL-enriched membrane microdomains, especially the significance of C24 fatty acid chains of 
LacCer in LacCer-mediated neutrophil functions. 
Lyn is a myristoylated protein, asso
located in the cytoplasmic leaflet of membrane bilayer. Our question is how LacCer is able to 
modulate a signal transducer molecule? Is it a direct interaction or is mediated by other 
molecules?  
On the basis of a series of data, our hypoteis is that GSL
mojety, have a specific role in modulating membrane interdigitation, reducing the membrane 
thickness and forming a specific 
leaflet and cytoplasmic proteins as well as among the 
side and components (Figure 6) [28]
 
 
 
 
Fig. 6 Schematic representation of the membrane with partially interdigitated layer
components with very long fatty
the insertion of the long hydrocarbonyl chain
 
in activation processes of neutrophils
 
the proteins interacting with LacCer in the innate response of human 
essential molecule(s) linking LacCer with Lyn in the LacCer
 
ciated with the membrane inner lipid layer and LacCer is not 
s, with a very long fatty acid chain of 
PM microdomanins. This would allow contact between the outer 
GSLs in the outer leaflet of the cytoplasmic 
. 
 acid, here represented by LacCer, requires a partial interdigitation to allow 
 reducing the membrane thickness (Adapted from [28])
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Several techniques are available for the detection of lipid rafts or organized domains, but the 
study of the PM lipid protein interactions is not easy because the biochemical assays available are 
very limiting. In particular the difficulty lies in the possibility to study the lipid-protein interaction 
directly at the level of PM of living cells and not in vitro studies.  
A methodology useful for the study of GSLs-proteins interaction is the photoaffinity labelling, 
which consist in the administration of photoactivable GSLs molecules (Figure 7), that are able to 
become components of the cell membrane, followed by illumination [37-46]. As radioactive tracer 
we used tritium, chosen because it does not change the physic-chemical properties of the 
molecules, it is not dangerous, whereas as photoactivable group we use a reactive azide.  
 
 
 
 
 
 
 
 
Fig. 7 General structure of a radioactive and photoactivable GSL derivate containing a nytrophenylazide. 
[3H]R is the tritium labeled ganglioside oligosaccharide chain.  
 
Linked to nitrophenyl, the azide becomes very sensitive to light when solubilized and in this 
condition it must handled with care and under dark conditions (red safelight). When illuminated, 
yield a very reactive nitrene intermediate that, by reactions of addition, insertion and nucleophilc 
attack, covalently binds to the molecules in the environment and in part link to the proteins 
(Figure 8). 
Thus, after the probe is taken up by the cells and becomes membrane component, the azide 
group will be deeply inserted into the membrane lipid bilayer. According to the scheme reported 
in Figure 7, when the photoactivable GSLs, inserted in the membrane level, is illuminated, the 
major part of it cross-links to membrane lipid molecules which are more abundant and close to 
the photoactivable group. A minor part of the nitrene-containing GSLs links to proteins and by a 
radioactive tracer, present in the molecule, is possible to detect the proteins cross-linked to 
photoactivable probe. 
Figure 9 shows the three possible types of GSLs-protein cross-linkage. Given the final azide 
position inside the PM, a cross linkage might occur with the lipid moiety of a GPI-anchored 
protein, with a hydrophobic aminoacidic stretch of a transmembrane protein, or with the fatty 
acid anchoring a protein to the cytoplasmatic side of the membrane. 
O
H HN
NH
HO H
O
O2N
N3
[3H]R
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Fig. 8 Scheme of reactions involving the azide before and after illumination. The reduction of azide is a 
rapid reaction inside the cells in the presence of reducing proteins such as glutathione or SH enriched 
proteins (from [43]).  
 
 
 
 
 
 
 
Fig. 9 Cartoon representing the protein-GSLs cross linkages that can be obtained after illumination of the 
photoactivable GSLs inserted into the PM (adapted from [43]). 
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To study the LacCer/Lyn interaction, the chemical group of Prof. Sonnino developed a radio-photo 
labeled analogue of C24-LacCer ([3H]-C24-(N3)-LacCer), with long acyl chain and C16-LacCer ([
3H]-
C16-(N3)-LacCer), with short acyl chain (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 Structure of a radioactive and photoactivable [3H]-C24-(N3)-LacCer, with long acyl chain and [
3H]-
C16-(N3)-LacCer, with short acyl chain. The photoactivable group, the nitrophenylazide, is located at the 
end of the acyl chain, while the tritium group is located in position 3 of shingosine.  
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MATERIALS 
Mouse anti-LacCer IgM T5A7 was established as described previously [47]. Mouse anti-LacCer IgM 
Huly-m13 was purchased from Ancell (Bayport, MN, USA). Rabbit anti-Lyn IgG, and mouse anti-Gαi 
were purchased Cell Signaling Technology (Beverley, MA, USA) and from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), respectively. All the other monoclonal antibody were 
purchased from BD Biosciences (San Jose, CA, USA). PE-conjugated anti Human CD11b and mouse 
IgGIK were from eBioscience (San Diego, CA, USA).  
Synthesized GSLs, C16:0 (palmitic acid)- and C24:0 (lignoceric acid)-LacCer were synthesized as 
described previously [48] 
Culture dishes IWAKI were purchased from Bibby Scientific (Tokyo, Japan). RPMI-1640, DMEM/F12 
and FBS were purchased from Nissui (Tokyo, Japan). PBS, BSA, DMSO, DFP, PMSF, TRIZMA, EDTA, 
NaCl, NaF, Triton X-100, Na3VO4 and sucrose were from Sigma-Aldrich (St. Louise, MO). Complete 
protease inhibitor cocktail (Complete) was obtained from Roche (Indianapolis, IN, USA). 
 
METHODS 
 
Cell Culture 
HL-60 cells were maintained in culture in RPMI-1640 medium supplemented with 10% FBS. To 
induce differentiation into neutrophilic lineage cells (D-HL-60 cells), HL-60 cells were cultured 
with 1.3% DMSO for 8 days. Differentiation was confirmed by CD11b expression on D-HL-60 cells 
using flow cytometry analysis [49].  
 
Flow cytometric analysis 
DMSO-treated and untreated HL-60 cell suspensions were labeled with phycoerythrin-conjugated 
antihuman CD11b antibody (eBioscience, San Diego, CA) or with phycoerythrin-conjugated mouse 
IgG1, kappa isotype control (eBioscience) for 30 min on ice, and then the expression of CD11b was 
analyzed by flow cytometry (FACScalibur; BD Biosciences,Mansfield, MA) [53]. 
 
Treatment of cell cultures with radioactive photoactivable LacCers. 
For loading of D-HL-60 cells with LacCer, aliquots of 10 ml D-HL-60 cells (2x107 cells/ml) in 
Dulbecco’s PBS were incubated with a mixture of 0.25ug of [3H]--(N3)LacCer and 0.25 μg of LacCer 
(final concentration 0.5 μg/ml) for 30 min at 20°C. After incubation, cells were washed once with 
10 ml PBS + 0.1%  BSA in DMSO to remove non incorporated or attached LacCer [48]. The cells 
were washed twice with 10 ml of cold PBS, and then 15 ml of cold PBS were added and the cells 
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were illuminated for 45 min under UV light (λ= 360 nm) on ice. All procedure before exposure to 
UV light were performed under red safelight [37-46]. Cells were collected and treated with 5mM 
DFP in PBS for 10 minutes on ice. After centrifugation at 270 g for 10 minutes, cell pellet (2x108 
cells) was lysed in the 1 ml of lysis buffer (1% Triton X-100, 10 mM Tris-HCl (pH7.5), 150 mM NaCl, 5 
mM EDTA, 1 mM DFP, 1mM Na3VO4, 1 mM PMSF and 1/20 (vol/vol) Complete Roche at 4°C for 20 
minutes. After Dounce homogenized (70 strokes), the lysate was centrifugated (1300g for 5 min) 
to remove nuclei and cellular debris, and the Post Nuclear Supernatant (PNS) was removed and 
transferred into new tubes. 
 
Determination of cell viability 
At the end of loading with radioactive and photoactivable LacCer cell viability was assessed by 
Tripan Blue exclusion methods [50,51].  
 
Preparation of SLs-enriched membrane domains by sucrose gradient 
centrifugation.  
The PNS fraction was mixed with an equal volume of 85% of sucrose (w/v) in 10 mM Tris Buffer HCl 
pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, placed at the bottom of a discountinuos sucrose 
concentration gradient (30-5%) in the same buffer and centrifugate (17h at 200,000g) at 4°C. After 
ultracentrifugation, eleven fraction were collected starting from the top of the tube. The light-
scattering band, corresponding to the DRM fraction, was located at the interface between 5% and 
30% sucrose and correspond to fraction 5. The entire procedure was performed at 0 to 4°C in ice 
immersion [33,52].     
 
Analysis of protein patterns 
PNS and sucrose gradient fraction obtained after cell photolabeling with [3H]-(N3)-LacCer were 
analyzed with SDS-PAGE. After separation, proteins were transferred to PVDF membranes. 
Proteins cross-linked with [3H]-(N3)-LacCer were analyzed by digital autoradiography. The 
presence of Lyn and G protein was assessed by immunoblotting with specific antidoby, followed 
by reaction with secondary horseradish peroxidase-conjucated antibody and enhanced 
chemioluminescence detection (Super Signal Pierce) [36-42] 
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Immunoprecipitation experiments 
The lysates (1.2x107 cell equivalent) or sucrose gradient fraction were diluted 10-fold volumes of 
immunoprecipitation buffer (50mM HEPES, pH 7.5, 1% Triton X-100, 150 mM NACl, 2mM Na3VO4, 
10 mM NaF, with 1/20 Complete) and then precleared by incubation with 30 μl rat anti-mouse 
IgM/IgG IgG-bound Dynabeads (Invitrogen) for 1 h at 4°C. After pre-cleaning, the supernatants 
were incubated with 5 μg anti-LacCer IgM Huly-m13 or normal mouse IgM overnight at 4°C for 
LacCer immunoprecipitation or with 5 μg anti-Lyn IgG or normal mouse IgG overnight at 4°C for 
Lyn immunoprecipitation, followed by incubation with 30 μl rat anti-mouse IgM/IgG IgG-bound 
Dynabeads for 4 h at 4°C. The immunoprecipitated beads were then washed three times with 
immunoprecipitation buffer and were denatured under nonreducing conditions and then 
separated on 7.5% polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) 
membranes. The Lyn and αGi were detected using SuperSignal™ reagent (Pierce Chemical Co., 
Rockford, IL, USA). 
In some experiment IP samples were treated with 1% SDS in lysis buffer at 100°C for 5 min, then 
diluted 10 fold with lysis buffer (0.1% SDS final concentration) and immunoprecipitated as above. 
These condition are known to breack up the membrane organization and to allow the 
disaggregation of DRM domains [54] 
 
Phagocytosis assays 
LacCer-loaded D-HL-60 cells were incubated with Alexa 647-conjugated NOZs at a concentration 
of 10 particles per cell for 45 min at 37°C in DMEM/F12. After incubation, cells were washed with 
ice-cold PBS and fixed with 2% paraformaldehyde in PBS for 20 min on ice. At least 200 cells per 
sample were counted using a Leica TCS-SP2 confocal microscope equipped with a Plan-
Apochromat ×100 oil differential interference contrast (DIC) objective (Leica Microsystems, 
Wetzlar, Germany), and phagocytic index was defined as percent-positive ingestion multiplied by 
the average number of phagocytosed particles per cell [35,55] 
 
Other experimental procedures 
The radioactivity associated with cells and with cell fractions, was determinate by liquid 
scintillation counting. Digital autoradiography of the PVDF membranes was performed with a 
Beta-Imager 2000 instrument (Biospace, Paris) 
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i. Effect of [3H]-C16/C24
On the bases of the previously experiment 
C16/C24-(N3)-LacCer around 0.5 μg/ml of cells. In t
production of superoxide.  
Like First step we performed experiment to verify cell toxicity due to the administration of photo
LacCer at this concentration, because these compounds are not natural compound but 
analogues. Cell viability was evaluated by Tripan Blue assay
not present alteration in cell proliferation and death in the presence of both 
and [3H]-C24-(N3)-LacCer, compared with untreated cells
 
 
Fig. 11 Photoactivable LacCer’s effect on D
 
 
ii. Radio-photo analog LacCer are “phisiologically” insert in the PM
The use of these derivates implies to demonstrate that they mimics as close as possible that of 
natural endogenous compounds.
essentially recovered in Triton
cells [13]. 
After the feeding of the cells with the photoactivable compound, cells were 
light, harvested, lysed in lysis buffer containg Triton X
homogenate were centrifugate at 1300xg for 5 minutes to obtain the PNS. PNS were loaded on a 
discontinuos sucrose gradient and ultracentri
were collect from the top of the tube. 
in activation processes of neutrophils
-(N3)-LacCer on D-HL-60 cells 
[33], we fixed the concentration of administrated 
his condition D-HL-60 cells shown an increased 
. As show in Figure 11, 
. 
-HL-60 cells’s viability.  
 From the previously experiment we know that LacCer is 
-X-100 insoluble DRM fraction, of neutrophilis as well as 
-100 and in order to remove nuclei cell 
fugated at 200000xg for 17h and eleven fraction
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-
D-HL-60 cells do 
[3H]-C16-(N3)-LacCer 
 
 
D-HL-60 
illuminated under UV 
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The radioactivity associated to each fraction was determinate by liquid scintillation counting. 
As show in Figure 12 in both treatments with
radoactivity, then LacCer, was largely associated with fraction 9
density fraction (HD fraction) that contain membrane solubized by the detergent and the higher 
quantity of cell proteins. Moreover som
corresponding to the low density fraction 
solubilization. The radioactivity associated in the bottom fraction is mainly due to the cross linking 
with lipid, that are the more abundant and close to the photoactivable group.
different distribution of radioactivity on gradient fraction from cell labelled with 
LacCer and from the cells labelled with
different physical property of these 2 compound, and need to be explore.
To understand if the radioactivity distribution was an artefact due to the illumination process, we 
also prepare the gradient fraction from no illuminating cells.
significant different in the distribution of radioactivity was obtained.
 
 
Fig. 12 Gradient fraction analysis. 
density fraction from illuminate and n
in activation processes of neutrophils
 [3H]-C16-(N3)-LacCer and [
3H]
-11, corresponding to the high 
e radioactivity was also associated with fraction 5
(DRM) that are resistent to the detergent 
 [3H]-C24-(N3)-LacCer. These probably is 
  
 Like show in the graph 
 
 
Distribution of total radioactivity ([3H]-C16/C24-(N
o illuminate cells 
DRM 
DRM 
DRM 
DRM 
HD      
HD      
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-C24-(N3)-LacCer, cell 
-6 
 We obtained a 
[3H]-C16-(N3)-
due to the 
(Figure 12) no 
 
3)-LacCer) in sucrose 
HD      
HD      
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To verify if these compound are biolog
60 cells after the loading with radio and photo activable compound. 
without illumination indicated that
microorganisms, whereas [3
that both the radio-photo-labeled analog of C24
inserted into the PM.  
Fig. 13 Phagocytosis index 
 
 
iii. Radio-photo-labeled analog of C24
associated with Lyn 
To examine interactions among LacCer and Lyn, we performed co
We initially performed immunopre
(N3)-LacCer and [
3H]-C24-(N3
immunoblotted for Lyn . Figure 14a 
antibody-immunoprecipitants from 
cells.  
In figure 14b we reported the radio
immunoprecipitants from 
radioactivity. 
 
in activation processes of neutrophils
ically active, we assessed the phagocy
 The phagocytosis assay 
 and [3H]-C24-(N3)-LacCer-loaded D-HL-
H]-C16-(N3)-LacCer--loaded D-HL-60 cells failed. 
-LacCer and C16-LacCer, are “physiologically” 
 
-LacCer but not C16
-immunoprecipitations assay. 
cipitation experiments of PNS from cells loaded with
)-LacCer. The immunoprecipitates were submitted to SDS
show the WB image: Lyn was recovered in anti
and [3H]-C24-(N3)LacCer but not [
3H]
-immuno assay using anti LacCer antibody indicating that the 
[3H]-C24-(N3)-LacCer but not [
3H]-C16-(N
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tosis activity of D-HL-
60 cells phagocytosed 
These results suggest 
-LacCer is directly 
 [3H]-C16-
-PAGE and 
-LacCer 
-C16-(N3)LacCer -loaed 
3)-LacCer contained 
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Fig. 14 Imumunoprecipitation of LacCer from D
(N3)-LacCer. a) Western Blotting analysis
 
 
To determine if the interaction between Lyn and LacCer cou
performed an experiment of immunoprecipitation for Lyn in disgregant conditions from DRM 
fraction isolated from the D-
After SDS-PAGE separation, Lyn was r
15a). However, [3H]-LacCer (radioactivity) 
cells loaded with analog of
directly connected to LacCer, when cells are loading with C24 LacCer, but not with C16 LacCer.
 
in activation processes of neutrophils
-HL-60 cells loaded with [3H]-C24
 b) Radio-immuno assay 
ld be a direct interaction, we 
HL-60 cells loaded with [3H]-C16-(N3)-LacCer and 
ecovered from both loaded cells by immunoblotting (Figure 
was only recovered in the immunoprecipitant from the 
 [3H]-C24-(N3)LacCer (Figure 14b). These results suggest that Lyn is 
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-(N3)-LacCer and [
3H]-C16-
[3H]-C24-(N3)-LacCer. 
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Fig. 14 Imumunoprecipitation of L
LacCer in disgregant conditions
 
iv. Identification of cross
We next examined LacCer-protein interactions occurring within the DRM and HD fractions of 
living cells performing a cross
LacCer(s). 
Target proteins were separated by SDS/PAGE
autoradiografy for 96 hr (Figure 16a)
complexes but not C16-LacCer
suggesting a specific association between LacCer and different DRM proteins. 
Moreover the same PVDF was immunostaning both for Lyn and G
corresponding to the Lyn protein
confirming a direct association of LacCer with Lyn and suggesting a possible interaction with Gαi 
protein.  
in activation processes of neutrophils
yn from D-HL-60 cells loaded with [3H]-C24-(N3)
. a) Western Blotting analysis b) Radio-immuno assay
-linkage proteins 
-linking assay using the photoactivable radioactive derivates 
, blotted on PVDF membrane and 
. A broad range of radioactivity reflecting C24
-protein complexes could be detected from 75 kDa to 20 
αi: a specific radioactive band 
 (56 kDa) and one corresponding to Gαi (41 kDa) were
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-LacCer and [3H]-C16-(N3)-
 
of 
visualized by 
-LacCer-protein 
kDa, 
 
 detected, 
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Fig. 16 Protein cross-linked with [
loaded with [3H]-C16-(N3)-LacCer and [
images. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in activation processes of neutrophils
3H]-(N3)-LacCer from DRM and HD fractions prepared from 
3H]-C24-(N3)-LacCer. a) Autoradiografy image b) Western Blotting 
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The innate immune system is the first line of defense against pathogenic microorganisms, such as 
bacteria, fungi, and viruses. Phagocytes, such as neutrophils and macrophages, play an important 
role in the innate immune system by recognizing, engulfing, and eliminating pathogens [29-32]. It 
has been suggested that lipid membrane microdomains/rafts of phagocytes are involved in these 
innate immune responses, including superoxide generation, cell migration, and phagocytosis. 
GSLs are highly enriched in specialized membrane microdomains (“lipid rafts”, caveolar domains 
and glycosynapses), and they participate to the process of transduction of information across the 
membrane. Recent proteomic analyses of microdomains from phagocytes have provided insight 
into membrane microdomain-mediated functions in the processes of phagocytosis [13-17,22-26].  
LacCer, a neutral GSL, is abundantly expressed on human neutrophils, and specifically recognizes 
several pathogenic microorganisms. LacCer forms membrane microdomains coupled with the Src 
family kinase Lyn on the PM, and ligand binding to LacCer activates Lyn, resulting in neutrophil 
functions, such as superoxide generation, phagocytosis and migration. In contrast, neutrophilic 
differentiated HL-60 cells do not have Lyn associated LacCer-enriched microdomains and lack 
LacCer-mediated functions. The presence of a LacCer molecular species with Cer containing a very 
long fatty acid chain is also required. In neutrophil PMs, the very long fatty acid C24:0 and C24:1 
chains are the main components of LacCer, whereas PM of D-HL-60 cells mainly includes C16-
LacCer species. LacCer species containing very long fatty acid chains are indispensable for the 
association of Lyn with LacCer-enriched microdomains and LacCer-mediated functions [13,28-35].  
With this project we want to study the role of very long fatty acid-LacCer species in the physical 
and functional coupling with Lyn and in microdomain-mediated functions in the processes of 
phagocytosis to determine the molecular mechanisms underlying these functions. For this 
pourpose, the chemical group of Prof. Sonnino developed the tritium-labeled and photoactivale 
LacCer derivatives with the aim to give a name to this proteins. 
This project was carried out in the Laboratory of Professor Kazuisa Iwabuchi, at the Juntendo 
University of Tokyo, where I spend 7 months.  
First step was to set up the correct condition for the use of the radio-photo labeled derivates. We 
started founding out the best conditions for the administration of these compound in cell in 
culture, and like reported in “Materials and Methods” and “Results” sections we fixed the 
concentration at 0.5 μg/ml of cell sunspecion for 30 minuts at 20°C. In these experimental 
condition we obtained a sufficient incorporation of radiophoto LacCer into the PM. Indeed this 
conditions allows us to be sure that LacCer stop at the level of PM and do not enter in the 
metabolic via.  
We also demonstrated the physiological activity of these derivated compound: they were 
incorporated into the PM and showed phagocitosis activity, mimics the natural compound. 
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To understand what’s happen at the level of 
and to recognize the protein associated to the LacCer environment.
By means of cross linking and immunoprecipitation experiments with photoactivable and 
radioactive [3H]-C16/C24-(N3)
direct interaction in LacCer-
results with analogues are encouraging. In fact, they seem to confirm the initial hypothesis 
related to the requirement of long chains LacCe
These results suggest that GSLs with a long fatty acid chain of Cer moiety, in our specific case 
LacCer, could be the key- player on the signal transduction across the cellular 
membrane interdigitation, reducing the membrane thickness and forming a specific 
microdomanins. We know that for LacCer mediated Lyn activation  is necessary:
species with Cer containing very long fatty acid chain, 
disaccharide structure of LacC
some specific protein. Chemical group of Prof. Sonnino is now working on the synthesis of  the 
tritiated and doubly photoactivable LacCer containing fatt
understand also which molecules are constituent of these domains in the external 
or CD14.  
 
Fig. 17  Cartoon of the possible organization of Lyn coupled LacCer
 
 
in activation processes of neutrophils
PM microdomain we prepared the DRM to analyzed 
 
-LacCer we showed that Lyn and LacCer with lon
enriched membrane domain from neutrophilic cells. 
r for the innate responses in human neutrophils. 
but also the presence of β
er.This means that the oligosaccharide chain is able to recognize 
y acid with long chain, that allow us to 
-enriched lipid rafts in neutrophilis. 
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SPHINGOLIPIDS in NERVOUS SYSTEM 
Among the tissues of the body, nervous tissue is one of the richest in lipid content. Apart from 
their quantitative importance, the lipids of the nervous tissue show a great deal of structural 
diversity. They are actively synthesized and increase substantially in quantity during the early 
phases of development of the nervous system. Lipids in brain tissue have an important role 
because they modify the structure, fluidity and functions of brain membranes. Lipid deposition 
and metabolism are connected with the biogenesis of some specialized membranes, such as 
myelin, clearly indicating a role for lipids in neural function. Lipids account for about 10% of the 
fresh weight and half the dry matter of the brain. 
Sphingolipids (SLs) are particularly abundant in the nervous system and gangliosides, sialic acid 
content glycosphingolipids (GSLs), are high enriched in neurons. A physiological regulatory role of 
SLs, and in particular of gangliosides, has been documented for biological events of great 
relevance for neural cell biology, such as neurotrophic factor signaling [1-4], neural cell adhesion 
and migration [2,5,6], axon guidance, synaptic transmission [2,7], neuron-glia interactions [8,9] 
and myelin genesis [10].  
It is possible to observe drastic and consistent changes in ganglioside pattern during neuronal 
development, particularly during the earliest stages. Many studies have shown that the 
qualitative and quantitative modifications in SLs expression in the nervous system during all 
phases of life. For this reasons the understanding of the metabolic regulation and the roles of SLs 
is a major challenge, and particular attention has been paid to determining the roles of SLs in 
neuronal development and in the central nervous system (CNS).  
The crucial role of GSLs in the development and maintenance of the proper functions of nervous 
system has been demonstrated by different evidences: 
 
i. GSL pattern undergoes deep qualitative and quantitative modifications during the 
development of the nervous system: the total ganglioside content increases a lot in the postnatal 
life in vertebrate brains and along in vitro differentiation of cultured neurons of different origin 
and in mouse neural precursor cells. These increases were accompanied by a dramatic shift from 
simple gangliosides (GM3 and GD3) to more complex species (GM1, GD1a, GD1b, GT1b). 
Sphingomyelin (SM) content also dramatically increased during in vitro differentiation in rat 
cerebellar neurons. Along the adult life, a progressive loss of gangliosides with aging has been 
reported in human and mouse brain. The most pronounced ganglioside changes associated with 
aging were an increase in the simpler gangliosides (GM3 and GD3) and a reduction of the complex 
gangliosides of the a-series (GD1a and GT1a) [12,13]. In addition to development- and age-
associated changes in the oligosaccharide portion of gangliosides, deep remodeling of their 
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hydrophobic portion, involving changes in both the long chain base and fatty acid composition of 
the ceramide (Cer) moiety, has been described in human [14,15] and rat brains [16-18], rat 
cerebellum [19] and cultured rat cerebellar neurons [11,20]. Before birth, only C18:0- and C18:1-
containing long chain bases were detectable in brain gangliosides [17]. C20-long chain bases in rat 
brain appeared after birth at a lower amount and gradually increased along aging in all brain 
gangliosides, reaching 27-55% of the total at the age of 2 years [16]. A similar switch from C18- to 
C20-long chain bases, both free and ganglioside-associated, was observed in neuronal cells during 
differentiation and aging in culture [11,10]. The increase in C20-long chain bases was generalized, 
but followed different trends for different gangliosides, indicating that the final molecular species 
composition for a certain ganglioside does not simply reflect the availability of different long 
chain bases as substrates for the biosynthetic pathway. In the ganglioside mixture from the brains 
of humans and different animals, 18:0 fatty acids generally comprise more than 80% of total fatty 
acid content, however complex changes in the fatty acid composition of different ganglioside 
classes have been reported along age. As example, the stearic acid content in C18-long-chain 
bases-containing gangliosides decreased with age in rat brain, with a concomitant increase in 
C16:0 and C18:1 fatty acids, while the fatty acid content of C20-long-chain bases-containing 
gangliosides was age-independent [16]. A greater short-chain fatty acid content in SM has been 
observed in young children and in a few cases of non-specific brain damage associated with 
demyelination [21,22]. 
 
ii. Experimental manipulations allowing modification of the concentration or pattern of GSLs 
in the plasma membrane (PM) profoundly affect the behavior of neural cells. The addition of 
exogenous gangliosides exerts neuritogenic, neurotrophic, and neuroprotective effects in 
cultured neurons and neural cell lines and in animal models of neural lesions [23,23-27]. In 
particular, selective depletion of cell surface SM and GSLs, achieved by treating living cells with 
bacterial sphingomyelinases or with endoglycoceramidase respectively, affected survival in 
neurotumoral cell lines and oligodendrocytes, axonal transport and sorting, and neuronal 
signaling transduction. 
 
iii. Many pieces of evidence indicated that SLs biosynthesis is necessary for nervous system 
development. Blockade of GSLs biosynthesis by pharmacological inhibition of GlcCer synthase or 
Cer synthase reduced axonal elongation, branching synapses formation and activity [28] in 
cultured hippocampal and neocortical neurons [29,30]. Neural cell-specific deletion of GlcCer 
synthase in mice led to severe neurological defects in the early postnatal life and death within 3 
weeks [31], demonstrating the importance of GSL for the maturation of the nervous system. On 
the other hand, pharmacologically induced stimulation of GSL biosynthesis stimulated neurite 
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outgrowth, formation of functional synapses and synaptic activity in cultured cortical neurons 
[28,32], and the induced expression of GD3 synthase was able to switch neuroblastoma cells to a 
differentiated phenotype [33]. NGF- and forskolin-induced neuronal differentiation in PC12 cells 
was accompanied by the up-regulation of several glycosyltransferase activities (GalGb3-, GM3-, 
GD1a- and GM2 synthases) [34], and bFGF-stimulated axonal growth in cultured hippocampal 
neurons resulted in the activation of Cer glucosyltranferase [35]. It has been recently suggested 
that the activity of the plasma membrane-associated ganglioside sialidase Neu3 might have a role 
in modifying the cell surface ganglioside composition, causing a decrease of GM3 and shift from 
polysialylated ganglioside species to GM1, with deep consequences on very important cellular 
events, including neuronal differentiation. In neuroblastoma cell lines, Neu3 expression increased 
during pharmacologically induced neuronal differentiation, and Neu3 gene transfection induced 
neurite outgrowth [36] and enhanced the effect of differentiating agents on the extension or 
branching of neuritis [37]. Conversely, inhibition of PM sialidase activity resulted in the loss of 
neuronal differentiation markers [38-40]. In cultured hippocampal neurons, Neu3 activity 
regulated the local GM1 concentration, determining the neurite axonal fate by a local increase in 
TrkA activity [41] and affecting axonal regeneration after axotomy [42]. 
It was recently reported that the sialidase Neu4 was dominantly expressed in the mouse brain 
[43-45] and its expression was relatively low in the embryonic stage and then rapidly increased at 
3-14 days after birth. Moreover during retinoic acid-induced differentiation, Neu4 expression was 
down-regulated in Neuro2a cells and the overexpression of Neu4 resulted in suppression of 
neurite formation; on the contrary Neu4 inhibition increases neurite formation [36,37,41,42]. Total 
β- Galactosidase activity was increased during the aging of the rat hippocampus in vitro and in 
vitro experiments [46]. These results suggest that a shift of ganglioside expression during 
development is regulated by changes of the expression level and activity of these key 
glycosyltransferases. Not only gangliosides but also other GSLs, such as GalCer and sulfatide, 
present drastic pattern shifts during development.  
 
 
SPHINGOLIPIDOSIS 
Several pieces of evidence indicate a bi-univocal relationship between nervous system 
dysfunction and altered SLs metabolism [47] : i) inherited disorders caused by defects in SLs 
metabolism are characterized by acute brain involvement [48]; this is the case of several 
lysosomal storage diseases, due to defects in SLs catabolism. Recently, the first example of a 
neurological human disease associated with the genetic disruption of ganglioside biosynthesis 
has been reported [49]; ii) even in the absence of genetic defects of SLs metabolism underlying 
                                                                          
 
the pathology, SLs metabolism is altered with important conseq
diseases.  
A wide group of inherited lysosomal storage disease is caused by defects in SL
(sphingolipidoses) (Figure 1) (reviewed in [48,50]
reduced (≤ 10% of normal le
cofactors or lysosomal transporters). As consequence the corresponding lipid substrate 
accumulates and is stored in lysosomal compartment. Obviously, this accumulation occurs mainly 
in those cell type and tissues in which the lipids are pronominally synthesized.  
For sphingolipidoses, the defective gene encodes for either a hydrolase involved in SL
catabolism, or an activator protein required for the proper activity of a SL
sphingolipidoses are characterized by severe neurological involvement. In particular, the most 
severe infantile forms are characterized by an acute brain involvement, usually leading to death in 
the early years of life. The enzymatic, genetic and molecu
deficiency have been extensively studied and basically elucidated for most of these diseases. 
 
 
 
Fig. 1: Sphingolipidosis (Adapted from [50])
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Unexpected alterations of SLs metabolism in Sphingolipidosis
On the other hand, the molecular mechanisms linking the intralysosomal accumulation of 
unmetabolized substrates to the onset of the pathology are basically unknown. However, it has 
been suggested that the primary defect might affects multiple secondary biochemical and c
mechanisms that could be indeed the main cause of tissue damage and death in sphingolipidosis
(Figure 2) [48]. Indeed, it has been shown that, in a mouse model of GM1 gangliosidosis, GM1 
accumulation in lysosomes resulted in an increase of the gang
(ER) and in lipid rafts from mitochondria
homeostasis in ER and mitochondria, and to ER stress
apoptosis [51,52]. SLs metabolism a
the recycle of catabolic fragments originated in the lysosomes for biosynthetic purposes is 
quantitatively relevant. Thus, it can be expected that the blockade of proper SL
lysosomal level would lead to the jamming of the overall flow of metabolites, with consequences 
on the SLs composition in all cellular regions, including the 
that the mechanisms for the in vivo regulation of 
novo synthetic flow, the extent of recycling of catabolic fragments and the enzyme activities of 
both the biosynthetic and catabolic pathways are likely subjected to a very complex regulation in 
vivo.  
 
Fig. 2 Secondary biochemical and cellular pathways in sphingolipidosis
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As a consequence, the loss of a certain enzyme activity within 
unexpected consequences. A recent example is represented by the 
mice [53,54]. In these mice, in addition to the expected reduction of the synthesis of 
downstream complex SL) containing very long fatty acids (C22
observed in the SL composition (including changes in the fatty acyl chain comp
cannot be simply ascribed to the lack of 
levels) and in the activity of other enzymes of SL
and neutral SMase activity (due to the incre
Indeed, secondary accumulation of gangliosides was observed in several lysosomal storage 
diseases, including sphingolipidosis with (GD, galactosialidosis, GM1 gangliosidosis) or without 
primary defects in ganglioside 
lysosomal storage diseases not affecting 
mucopolysaccharidosis) (reviewed in [55]). Most commonly, accumulated gangliosides were the 
monosialogangliosides GM3 and GM2, that are relatively minor components in 
tissues. GM3 and GM2 accumulated in neurons from human patients and animal models [56] of 
NPD type C (due to a defect in the cholesterol
typical human severe case of NPD type A (caused by defective acid 
It has been suggested that these unexpected changes might be due to a jamming of the 
intracellular traffic of GSLs, with a consequent lack of feed
the Golgi/trans-Golgi-network [55,58]. However, secondary gangliosides accumulation and, more 
in general, secondary alterations of other lipid metabolism in sphingolipidosis has never been 
systematically investigated.  
 
NIEMANN-PICK DISEASE TYPE A
NPD types A and B are caused by mutations in the 
lysosomal enzyme required for the hydrolysis of SM into 
Fig.3 Nieman-Pick disease. 
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As the consequence of this, SM is accumulated in lysosomes of NPD patient cells, and both NPD 
type A and B are classified as lysosomal storage diseases [62]. Both forms of the disorder are 
characterized by progressive visceral organ abnormalities [63]. However, NPD
characterized by a higher r
neurological involvement, while NPD type A, with less enzyme residual activity 
neurodegenerative disorder that leads to death by three years of a
To better understand the pathogenesis of this disease and to evaluate the role of 
deficient mouse line (ASMKO) has been developed by gene targeting using homologous 
recombination in embryonic stem cells. The wild
the insertion of neomycin (neo
mice mimics all the symptoms of the lethal, neurovisceral form of human NPD type A: mice 
accumulate SM in the reticuloendothelial syst
the brain. They exhibit hepatosplenomegaly and during the progression of the disease, these 
mice show a drastic degeneration of Purkinje cell layer in the cerebellum that is associated to the 
appearance of tremors, ataxia and impairment of motor coordination. The life span of ASMKO is 
limited to about eight months 
 
Fig. 4. Schematic representation of the ASM replacement vector. 
exons spanning about 4.5kb. The location of the sense and antisense PCR primers (PS and PA1) used for 
detection of the endogenous mouse gene are shown. 
PGKneo expression cassette was in
the ASM coding sequence. An HSV
TAG termination codon. c. The disrupted ASM. The location of the neo
used. 
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) resistance gene (Figure 4). The resulting phenotype of these 
em of liver, spleen, bone marrow and lung and in 
[65,66].  
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b. the ASM replacement vector. Note that the 
serted into exon 2 of the ASM gene in the reverse orientation relative to 
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is a severe, 
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M gene, consisting in six 
isense PCR primer (PA2) 
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To better understand the secondary biochemical mechanism underling the pathogenesis and the 
importance of the secondary alterations of SL metabolism on lysosomal diseases, we decided to 
analyze the lipid composition of CNS and extraneural tissues from the ASMKO mouse, the animal 
model of NPD type A. 
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MATERIALS 
Commercial chemicals were of the highest purity available, common solvents were distilled 
before use and water was doubly distillated in a glass apparatus. Lipids to be used as standard 
were extracted from rat brain, purified [67], and structurally characterized [68]. High 
performance thin layer chromatography (HPTLC) plates were from Merck (Darmstadt, Germany). 
RC DC™ protein assay kit was from Bio-Rad (Hercules,CA,USA). Bovin serum albumin was from 
Sigma-Aldrich (St. Louis, MO).  
 
METHODS 
Animals 
The ASMKO mouse model [65] was backcrossed onto the C57BL/6N strain at the Charles River 
Laboratory, Milan, Italy. Starting from heterozygous mice, homozygous mice colonies were 
established: wild type (WT) mice (C57BL/6N; ASM+/+) used as control and mutant (ASMKO) mice 
(C57BL/6N; ASM-/-). Mice were bred according to the NIH Guide for the Care and Use of 
Laboratory Animals. Genotypes were checked by PCR [65]. Mutants and control mice were killed 
with CO2. 
 
Tissue lipid analysis 
Tissues from ASMKO and WT mice were weighed and homogenized in iced Millipore water (500 
mg of fresh tissue/mL); For lipid analysis we extracted the whole tissue from a single animal. The 
homogenates were sonicated at ice temperature, snap-frozen and lyophilized; lipids were 
extracted with chloroform/methanol/water 20 : 10 : 1 (v/v/v) three times. Total lipid extracts were 
subjected to a two-phase partitioning leading to the separation of an aqueous phase containing 
gangliosides and an organic phase containing all the other lipids [69]. The ganglioside content of 
each total tissue was determined in the aqueous phases as lipid-bound sialic acid using the 
resorcinol method [70] while the phospholipid content was determined as phosphate in the 
organic phases following perchloric acid digestion using the method of Bartlett [71]. The SM 
content was determined in the organic phase after alkaline treatment. 
Lipids were separated by monodimensional HPTLC carried out using the following solvent 
systems: chloroform/methanol/0.2% calcium chloride 60:35:8 (v/v/v) for phospholipids and SM, 
hexane/ethyl-acetate 3:2 (v/v) for cholesterol, and chloroform/methanol/0.2% calcium chloride 
50:42:11 (v/v/v) for gangliosides.  
Separated lipids were identified on the basis of co-migration with lipid standards [72].  
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Phospholipids were detected by spraying the HPTLC with a molybdate reagent [73]. Cholesterol 
was visualized by spraying the HPTLC with anisaldehyde and quantified by densitometry and 
comparison with 0.1-0.2 µg of a standard compound [72]. SM was recognized using 15% 
concentrated sulfuric acid in 1-butanol [72]. Gangliosides were visualized after separation on 
HPTLC by specific detection with the p-dimethylaminobenzaldehyde reagent [74].  
The relative amounts of lipids associated with each band after HPTLC separation were determined 
by densitometry using the Molecular Analyst program (Bio-Rad Laboratories, Hercules, CA, USA). 
The number of sialyl residues was taken into account for analysis of ganglioside content. The 
mass content of each phospholipid, or ganglioside, was calculated on the basis of the percentage 
distribution of total phospholipid or ganglioside content, determined as described above [75,72]. 
The protein content was determined in all samples using the RC DC™ protein assay and BSA as the 
reference standard. 
 
Statistical analysis 
Experiments were performed on three different tissue samples from different animals for each 
genotype and age group. The results are expressed as mean value ± S.D. Statistical analysis of the 
data was performed by one-way ANOVA followed by the Student-Newman-Keuls' test. p<0.05 
was considered significant (compared with WT) and p values are indicated in the legend of each 
figure and/or table. 
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We analyzed the lipid composition of CNS and extraneural tissues from the ASMKO mouse, the 
animal model for NPD type A
stem) and extranervous (spleen, kidney, pancreas, liver) tissues with chloroform/methanol/water, 
and total lipid extracts were submitted to a two
were analyzed for total phospholipid and cholesterol content and phospholipid pattern, aqueous 
phases were analyzed for total ganglioside content and ganglioside patterns. 
 
i. Total phospholipid content 
Total and individual phospholipid contents are reported in 
HPTLC analysis. SM accumulation was evident in 5
mice in all nervous (Table I) and extranervous (Table II) tissues analyzed, and it was much higher 
in extranervous (from 30- to 40
fold higher). The total phospholipid phosphorous content in ASMKO vs. WT mice was unchanged 
in nervous system tissues (Tables I and III), while it was significantly increased in spleen,
liver and, at a lesser extent, pancreas (Table II). The distribution among different 
glycerophospholipid species, evaluated by 
extranervous tissues from both ASMKO and WT mice (Tables I and II). 
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 [90]. Lipids were extracted from nervous (brain, cerebellum, brain 
-phase partitioning. The resulting organic phases 
 
Tables 1, 2, and 3
-month-old ASMKO respect to wild
-fold higher in ASMKO than in WT) than in nervous tissues (4
HPTLC, was substantially unchanged in nervous and 
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-type (WT) 
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 kidney, 
 
                                                                          
 
 
 
Fig. 5 HPTLC phospholipid patterns from 5 month old WT and ASMKO mouse tissues. 
extracted with chloroform/methanol/water 20:10:1 (v/v/v). Total lipid extracts were subjected to a two 
phase partitioning [76]. (a) The endogenous phospholipi
and brain stem were separated from the organic phase, corresponding to 100 µg of tissue proteins, and (b) 
endogenous phospholipids from WT and ASMKO mouse spleen, kidney, pancreas and liver were separated 
from the organic phase, corresponding to 300 µg or 30 µg of tissue proteins for WT and ASMKO tissue, 
respectively, by mono-dimensional HPTLC. The solvent system was chloroform/methanol/0.2% calcium 
chloride 60:35:8 (v/v/v) and visualization was carried out with 
representative of those obtained in three different experiments. (PE, phosphatidylethanolamine; PC, 
phosphatidylcholine).  
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Lipids were 
  
Table I Phospholipid content in 5 month old WT and ASMKO mouse CNS tissue. 
Data are expressed as nmoles/mg of tissue wet weight (**, p<0.001 versus WT). The results are expressed as means values ± S.D. for three different experiments.  WT, wild-type; ASMKO, acid 
sphingomyelinase knockout; PE, phosphatidyethanolamine; PC, phosphatidylcholine;  PI, phosphatidylinosiltol;  PS, phosphatidylserine; SM, sphingomyeline.  
 
 
    Table II Phospholipid content in 5 month old WT and ASMKO mouse extra-neural tissue. 
    
Data are expressed as nmoles/mg of tissue wet weight .(*, p<0.005 versus WT; **, p<0.001 versus WT). The results are expressed as means values ± S.D. for three different experiments.  WT, 
wild-type; ASMKO, acid sphingomyelinase knockout; PE, phosphatidyethanolamine; PC, phosphatidylcholine;  PI, phosphatidylinosiltol;  PS, phosphatidylserine; SM, sphingomyeline.  
 
 
 
 
 
 Phospholipids PC PE PI+PS SM Others Phospholipids 
 WT ASMKO WT ASMKO WT ASMKO WT ASMKO WT ASMKO WT ASMKO 
CNS Tissues             
BRAIN 57.41 ± 2.84 54.62 ± 2.41 22.39 ± 1.11 19.51 ± 1.07 21.17 ± 0.99 18.34 ± 0.83 11.81 ± 0.57 9.94 ± 0.53 1.33 ± 0.07 6.42 ± 0.32** 0.71 ± 0.04 0.41 ± 0.01 
CEREBELLUM 51.96 ± 2.54 58.03 ± 2.12 21.84 ± 0.98 19.76 ± 0.92 21.17 ± 1.06 21.24 ± 1.01 7.98 ± 0.32 9.05 ± 0.39 0.92 ± 0.04 6.81 ± 0.34** 0.05 ± 0.01 1.17 ± 0.06 
BRAIN STEM 69.75 ± 3.42 71.85 ± 2.96 19.99 ± 0.89 21.02 ± 1.02 37.07 ± 1.85 35.04 ± 1.44 11.34 ± 0.05 10.51 ± 0.51 1.35 ± 0.06 5.23 ± 0.21** n.d. 0.05 ± 0.01  
             
Phospholipids PC PE PI+PS SM Others Phospholipids 
 WT ASMKO WT ASMKO WT ASMKO WT ASMKO WT ASMKO WT ASMKO 
Extra-neural Tissues             
SPLEEN 18.76 ± 0.75 81.55 ± 1.16** 14.44 ± 0.66 22.49 ± 0.85** 2.62 ± 0.12    5.85 ± 0.25 0.44 ± 0.02 n.d. 1.19 ± 0.06 53.16 ± 2.51** 0.07 ± 0.02 0.05 ± 0.01 
KIDNEY 36.83 ± 1.06 69.57 ± 1.41** 18.07 ± 0.79  26.17 ± 1.36* 15.23 ± 0.64  14.60 ± 0.71 0.36 ± 0.01 0.77 ±0.031 0.20 ± 0.09 25.14 ± 1.09** 2.97 ± 0.17 2.89 ± 0.15 
PANCREAS 20.41 ± 1.62 29.27 ± 1.33* 15.46 ± 0.67  13.59 ± 0.03 1.42 ± 0.07    0.99 ± 0.04 3.17 ± 0.15 3.96 ± 0.16    0.20 ± 0.03 7.78 ± 0.74* 0.16 ± 0.01 2.95 ± 0.13 
LIVER 30.05 ± 1.37 86.81±2.79** 18.77 ± 0.91 34.53 ± 1.57** 6.62 ± 0.27 14.15 ± 0.66* 3.31 ± 0.16 5.11 ± 0.26 1.10 ± 0.05 32.97 ± 0.32** 0.25 ± 0.02 0.05 ± 0.01 
  
Table III  Sphingomyelin content in WT and ASMKO mouse tissue 
  Phospholipids Total SM Lower Band (C16+C18) Upper Band (C24) 
 WT        ASMKO WT ASMKO WT ASMKO WT ASMKO 
CNS Tissues         
BRAIN         
0 day 25.82 ± 2,84 30.09 ± 1,78 0.30 ± 0.02     0.38 ± 0.02ᵟ 0.23 ± 0.01     0.29 ± 0.01ᵟ 0.07 ± 0.01      0.09 ± 0.01 
15 days 42.57 ± 2,56 42.65 ± 3,81 0.81 ± 0.03     1.10 ± 0.05* 0.65 ± 0.02     0.89 ± 0.04* 0.16 ± 0.01 0.21 ± 0.01* 
1 month  46.81 ± 2,04 39.47 ± 3,86 1.30 ± 0.06  2.49 ± 0.12** 1.11 ± 0.05 2.24 ± 0.11** 0.19 ± 0.01 0.25 ± 0.01* 
2.5 months 51.67 ± 1,71 49.23 ± 1,67 1.34 ± 0.05  7.29 ± 0.31** 1.11 ± 0.04 6.69 ± 0.29** 0.23 ± 0.01    0.60 ± 0.02** 
5 months 57.41 ± 2.84 54.62 ± 2.41 1.33 ± 0.07 6.42 ± 0.32** 1.16 ± 0.06 6.05 ± 0.30** 0.17 ± 0.01    0.37 ± 0.02** 
Extra-neural Tissues (5 months)         
SPLEEN 18.76 ± 0.75    81.55 ± 1.16** 1.19 ± 0.06 53.16 ± 2.51* 0.98 ± 0.05 43.68 ± 2.06** 0.21 ± 0.01   9.48 ± 0.45** 
KIDNEY 36.83 ± 1.06    69.57 ± 1.41** 0.20 ± 0.09    25.14 ± 1.09** 0.15 ± 0.07 19.22 ± 0.83** 0.05 ± 0.02   5.92 ± 0.26** 
PANCREAS 20.41 ± 1.62 29.27 ± 1.33* 0.20 ± 0.03        7.78 ± 0.74* 0.16 ± 0.02     6.32 ± 0.59* 0.04 ± 0.01     1.46 ± 0.15* 
LIVER 30.05 ± 1.37   86.81 ± 2.79** 1.10 ± 0.05     32.97 ± 0.32** 0.96 ± 0.04 28.84 ± 0.28** 0.14 ± 0.01   4.13 ± 0.04** 
         
Data are expressed as nmoles/mg of tissue wet weight (ᵟ, p<0.01 versus WT; *, p<0.005 versus WT; **, p<0.001 versus WT). The results are expressed as means values ± S.D. for 
three different experiments. WT, wild-type; ASMKO, acid sphingomyelinase knockout; SM, sphingomyeline.  
                     
 
 
 
 
 
 
 
 
  
Table  IV  Ganglioside content in WT and ASMKO mouse tissue 
 
  
Gangliosides GM3 GM2 GM1 
 WT ASMKO WT ASMKO WT ASMKO WT ASMKO 
  CNS Tissues         
  BRAIN         
1 month 0.653 ± 0.053   0.725 ± 0.036 0.010 ± 0.002    0.018 ± 0.007 0.007 ± 0.003   0.045 ± 0.026 0.133 ± 0.019 0.136 ± 0.011 
   2.5 months 0.682 ± 0.032 0.770 ± 0.027† 0.013 ± 0.001  0.037 ± 0.007† 0.013 ± 0.002 0.053 ± 0.007† 0.132 ± 0.012 0.140 ± 0.015 
5 months 0.741 ± 0.022 0.887 ± 0.037† 0.017 ± 0.005  0.064 ± 0.011* 0.007 ± 0.001 0.097 ± 0.012† 0.169 ± 0.021 0.162 ± 0.017 
  CEREBELLUM         
 1 month 0.591 ± 0.043   0.586 ± 0.073 0.012 ± 0.002 0.018 ± 0.008 0.007 ± 0.001   0.031 ± 0.018 0.035 ± 0.003 0.028 ± 0.007 
2.5 months 0.588 ± 0.031 0.678 ± 0.024† 0.022 ± 0.001   0.027 ± 0.002† 0.011 ± 0.001 0.065 ± 0.014† 0.045 ± 0.012 0.062 ± 0.015 
    5 months 0.631 ± 0.051 0.831 ± 0.092† 0.018 ± 0.001   0.039 ± 0.007† 0.010 ± 0.002 0.089 ± 0.015† 0.052 ± 0.005 0.066 ± 0.017 
  BRAIN STEM         
    1 month 0.591 ± 0.065   0.635 ± 0.073 0.008 ± 0.002 0.011 ± 0.005 0.007 ± 0.001 0.017 ± 0.003† 0.049 ± 0.007    0.047 ± 0.09 
    2.5 months 0.507 ± 0.036 0.631 ± 0.035† 0.007 ± 0.001   0.014 ± 0.002† 0.007 ± 0.003 0.019 ± 0.005† 0.070 ± 0.021 0.059 ± 0.014 
 5 months 0.511 ± 0.047 0.650 ± 0.045† 0.005 ± 0.001   0.029 ± 0.005† 0.006 ± 0.002 0.037 ± 0.009† 0.099 ± 0.006 0.097 ± 0.009 
Extra-neural Tissues        
LIVER 0.062 ± 0.052 0.346 ± 0.046* 0.009 ± 0.001 0.124 ± 0.013* 0.053 ± 0.007 0.222 ± 0.024* n.d. n.d 
GD3 GD1a GD1b GT1b Others ganglioside 
 WT ASMKO WT ASMKO WT ASMKO WT KO WT ASMKO 
  CNS Tissues           
  BRAIN           
1 month 0.034 ± 0.004 0.043 ± 0.005 0.300 ± 0.057 0.278 ± 0.029 0.062 ±  0.012 0.071 ± 0.014 0.086 ± 0.007 0.100 ± 0.013 0.021 ±  0.009 0.034 ± 0.012 
   2.5 months 0.042 ± 0.003 0.065 ± 0.007 0.295 ± 0.035 0.270 ± 0.061 0.068 ± 0.013 0.077 ± 0.007 0.097 ± 0.009 0.101 ± 0.007 0.022 ± 0.011 0.027 ± 0.006 
5 months 0.042 ± 0.012 0.067 ± 0.014 0.306 ± 0.027 0.279 ± 0.028 0.066 ± 0.007 0.071 ± 0.003 0.101 ± 0.017 0.104 ± 0.010 0.033 ± 0.007 0.043 ± 0.005 
  CEREBELLUM           
 1 month 0.069 ± 0.007 0.073 ± 0.017 0.101 ± 0.015 0.118 ± 0.019 0.040 ± 0.005 0.060 ± 0.012 0.239 ± 0.031 0.205 ± 0.023 0.088 ± 0.007 0.053 ± 0.017 
2.5 months 0.070 ± 0.016 0.074 ± 0.009 0.094 ± 0.021 0.096 ± 0.012 0.053 ± 0.009 0.062 ± 0.010 0.241 ± 0.052 0.235 ± 0.013 0.052 ± 0.009 0.057 ± 0.003 
    5 months 0.063 ± 0.019 0.065 ± 0.015 0.106 ± 0.017 0.146 ± 0.020 0.077 ± 0.012 0.061 ± 0.005 0.244 ± 0.047 0.256 ± 0.023 0.061 ± 0.016 0.109 ± 0.027 
  BRAIN STEM           
    1 month 0.027 ± 0.003 0.030 ± 0.006 0.108 ± 0.027 0.119 ± 0.027 0.088 ± 0.013 0.097 ± 0.023 0.185 ± 0.032 0.181 ± 0.016 0.119 ± 0.024 0.133 ± 0.021 
    2.5 months 0.023 ± 0.012 0.050 ± 0.016 0.075 ± 0.007 0.094 ± 0.011 0.072 ± 0.003 0.104 ± 0.034 0.133 ± 0.009 0.153 ± 0.013 0.120 ± 0.018 0.138 ± 0.007 
 5 months 0.029 ± 0.007 0.034 ± 0.007 0.058 ± 0.009 0.065 ± 0.012 0.077 ± 0.015 0.097 ± 0.012 0.127 ± 0.043 0.145 ± 0.024 0.110 ± 0.021 0.146 ± 0.019 
Extra-neural Tissues          
LIVER n.d n.d n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
                                                                          
 
ii. Cholesterol content 
Cholesterol content was not significantly different in nervous tissues from 5
ASMKO mice (Figure 6a), while a signif
spleen, kidney and liver from ASMKO mice (Figure 6
 
Fig. 6 Cholesterol content in 5 month old WT and ASMKO mouse
were extracted and partitioned as descri
quantitatively analyzed as described previously [72]. Data are expressed as nmoles cholesterol per mg of 
tissue wet weight (*, p < 0.005 versus WT; **, 
S.D. values for three different experiments.
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icant increase in cholesterol content was detected in 
b). 
 (a) CNS and (b) extraneural tissue. Lipids 
bed in the legend of Fig. 1. Cholesterol in the organic phases was 
p < 0.001 versus WT). The results are
 
 
81 
-month-old WT and 
 
 expressed as means ± 
                                                                          Secondary accumulation of gangliosides; the case of Niemman Pick type A 
82 
 
iii. SM pattern 
SM accumulation was followed in brains from ASMKO and WT mice along age from birth until the 
age of 5 months (Table III). SM accumulation occurred very soon in the postnatal life and was 
progressive along time; it was already significant at 0 days and it reached a plateau around 2.5 
months of age, when SM level in ASMKO brain was about 6-fold higher than in WT brain, 
remaining basically unchanged up to the age of 5 months, in agreement with previously published 
results [76,77]. Total phospholipid content in brain was similar in ASMKO and WT mice at all ages 
(Table III), indicating a significant reduction of glycerophospholipids in ASMKO brain along time. 
As other SL, SM is present in all tissues as a mixture of molecular species differing for their fatty 
acid composition [78]. HPTLC analysis of alkaline-treated organic phase lipids under the 
experimental conditions used allowed to separate 2 bands for SM: the lower migrating band 
corresponds to SM molecular species containing C18 and C16 fatty acids (mainly stearic acid), 
while the upper migrating band corresponds to SM molecular species with longer chain fatty 
acids, (mainly C24) [79]. In extranervous tissues, both SM bands accumulated in ASMKO mice at a 
similar extent (Table III ad Figure 7b). As example, in liver the ratio between lower and upper 
migrating bands was 6.9 in both ASMKO and WT mice (Figure 7b). On the other hand, in ASMKO 
brain the lower SM band was preferentially accumulated (Table 3). At 15 days of post-natal age, 
when SM accumulation was already evident, the ratio between lower and upper SM band was 
identical in WT and ASMKO brain, while at 1 month of age this ratio was already 1.4 fold higher in 
ASMKO than in WT and at 5 months it reached 2.5-fold in ASMKO vs WT (Figure 7a), clearly 
indicating that, in ASMKO brain, SM molecular species containing shorter fatty acyl chains (C18 
and C16) accumulate at a higher level that SM species with longer fatty acids (C24), in agreement 
with preliminary observations in purified myelin from ASMKO mice [79] 
 
                                                                          
 
Fig. 7 Ratios between SM in the lower and upper migrating bands in WT (light grey) and ASMKO (black) 
mouse tissues. Lipids were extracted as described in the legend of F
submitted to alkaline treatment followed by partitioning to remove glycerophospholipids. The alkali
treated organic phase was analyzed by mono
bands. The relative amounts of SM associated with the upper and lower migrating bands were determined 
by densitometry. (a) CNS tissues (0 days, 15 days, 1 month, 2.5 months and 5 months) (b) Extra
tissues (5 months). Data are expressed as the ratio of arbitrary opti
and C24 SM (*, p < 0.005 versus WT; **, 
values for three different experiments.
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ig. 1. The organic phase obtained was 
-dimensional HPTLC, allowing to resolve SM in two separate 
cal density units between C18/C16 SM 
p < 0.001 versus WT). The results are expressed as means ± S.D. 
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iv. Ganglioside pattern 
In addition to the expected SM accumulation, we
all ASMKO mouse tissues investigated, with the exception of spleen (Table IV). The total 
ganglioside content was moderately but significantly higher in nervous tissues from ASMKO 
respect to WT mice already 
observed in the cerebellum at 5 months (+43% respect to WT). Ganglioside accumulation was 
much more pronounced in liver (Table IV): at 5 months of age, ganglioside content in liver was 6
fold higher in ASMKO mice respect to controls. The chromatographic analysis of ganglioside 
patterns revealed that only the monosialoganglioside GM3 and GM2 were accu
tissues (Figure 8 and Table IV). Since GM3 and GM2 are normally minor components o
ganglioside mixture from nervous tissues, while they are among major gangliosides from 
extraneural tissues, their preferential accumulation clearly explains the quantitative differences 
observed between neural and extraneural tissues. In ASMKO brain,
was already significant at the age of 1 month. Both gangliosides accumulated with time, but with 
a different trend, and at 5 months of age GM2 levels were about 10
respect to WT, while GM3 levels 
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 found an increase in the gangliosides content in 
at 2.5 month of age (Table IV). The maximal accumulation was 
 GM3 and GM2 accumulation 
-fold higher in ASMKO brain 
were about 3-fold higher (Figure 8). 
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Fig. 8 Ganglioside patterns in WT and ASMKO mouse brain (panel a, 1, 2.5 and 5 months) and liver (panel b, 
5 months). Lipids were extracted and partitioned as described in the legend of Fig. 1. The endogenous 
gangliosides from WT and ASMKO tissues were separated from dialyzed aqueous phases (corresponding to 
300 µg of tissue proteins for brain and to 2.5 mg and 1 mg of tissue proteins for WT and ASMKO liver, 
resepctively) by mono-dimensional HPTLC, using the solvent syst
chloride 50:42:11 (v/v/v) and were recognized by specific detection with the p
[74]. Patterns are representative of those obtained in three different experiments. The relative amounts of 
each ganglioside were determined by densitometry. The ganglioside content in each sample was 
determined as lipid-bound sialic acid using the resorcinol method [70] and the number of sialic residues was 
taken into account for analysis of gangliosides content. The 
d) were calculated on the basis of the ganglioside percentage distribution. Data in panels c and d are 
expressed as nmoles gangliosides/ mg of tissue wet weight. The results are expressed as means ± S.D. 
values for three different experiments (**, 
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mass contents of GM3 and GM2 (panels c and 
p<0.001 versus WT).  
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Lysosomal storage disorders are caused by the defective activity of lysosomal proteins, which 
results in the intra-lysosomal accumulation of non-degraded metabolites. For a wide group of 
disorders, the defective enzyme is a hydrolase involved in SL catabolism. Most sphingolipidoses 
are characterized by prominent neurological involvement. In particular, the most severe, infantile 
forms presents with acute brain involvement leading to death within the first year of life. Juvenile 
and adult forms present both neurological and peripheral symptoms.  
The enzymatic, genetic and molecular bases underlying the metabolic deficiency have been 
extensively studied and basically determined for most of these diseases. However, little is known 
about the secondary biochemical and cellular pathways that are affected in these diseases, and 
that eventually result in cell and tissue dysfunction. In other word, we don’t know why does the 
lysosomal accumulation of a particular un-metabolized substrate causes the pathology: it is clear 
that the intralysosomal accumulation of non-metabolized substrates is the primary cause of the 
disease, but the wide range of disease symptoms indicates that many secondary biochemical and 
cellular pathways are affected. Any of these events could be indeed the main cause of tissue 
damage and death in sphingolipidosis. 
It is clearly emerging that, in several sphingolipidosis, complex changes in SL metabolism are 
observed, that cannot be explained solely on the basis of the genetic and/or enzymatic defect 
that represents the primary cause of the diseases, or of an impairment of the function of 
lysosomes, the primary cellular target in these pathologies. Secondary accumulation of 
gangliosides has been reported in several sphingolipidosis, even if this aspect has never been 
investigated. 
From this point of view, our findings in the ASMKO mice, the animal model of NPD type A, are 
particularly interesting. In ASMKO mice, we observed the preferential accumulation of SM 
molecular species with shorter acyl chains in the nervous system, but not in extranervous tissues, 
and the accumulation of GM3 and GM2 gangliosides in both neural and extraneural tissues. The 
unbalance toward C18/C16-containing SM species was detectable as early as SM accumulation 
started, and monosialoganglioside accumulation followed immediately afterwards. At least one 
report indicates that monosialoganglioside accumulation also occurs in the human pathology 
[57], while no information is available on the molecular composition of the accumulated SM. Fatty 
acid composition of SM from human cerebral white matter was reported to be abnormal in 
patients with juvenile and adult Huntington’s disease, with a shift toward shorter chain fatty acid 
[80].  
Clearly, the lack of ASM by itself is not sufficient to explain these unexpected changes in lipid 
composition. Remarkably, in many neurological disorders, including Alzheimer’s, Parkinson’s and 
Creutzfeldt-Jakob diseases, apparently not related to alterations of SL metabolism or of 
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lysosomal function, a general decrease of ganglioside levels is accompanied by a marked increase 
in the levels of simpler gangliosides [47]. These changes in SL patterns should thus represent the 
effect of secondary biochemical pathways altered as a consequence of a non-related primary 
cause. The mechanisms underlying these changes still remain to be elucidated and are probably 
the result of changes in the expression and/or activity of more than one single enzyme, of 
anomalies in the traffic of the substrates and of complex changes in the substrate/product 
concentrations in multiple cellular compartments. Thus, therapeutic strategies focused on a 
single enzyme activity might not necessarily represent a choice that can correct all of the 
metabolic abnormalities. Several pieces of evidence also suggest that altered SL metabolism 
might result in a non-physiological PM composition and organization, leading to altered plasma 
membrane-originated signaling pathways that could be relevant to the onset of the cellular 
damage and of tissue pathology [62]. This hypothesis has been recently confirmed by several 
observations. In a cell model of Gaucher disease, impaired lysosomal catabolism of GlcCer led to 
the accumulation of GlcCer at the PM level in lipid rafts, possibly explaining the altered lipid and 
protein sorting observed in this pathological condition [81]. Psychosine (galactosylsphingosine), 
one of the galactoslylsphingolipids that accumulates in the brain of Krabbe disease (human 
globoid cell leukodystrophy) patients due to the deficient activity of -galactosylceramidase, 
accumulates in lipid rafts from brain and sciatic nerve from twitcher mice (the animal model for 
the infantile variant of the disease) and from human Krabbe patients, leading to an altered 
distribution of lipid raft proteins and to inhibition of protein kinase C [82]. Brain pathology in 
ASMKO mice is probably at least in part due to a PM involvement [83], possibly associated with a 
non-conventional lipid raft organization [77,78].  
For SM, the shift toward molecular species with shorter fatty acids has been associated in some 
cases with myelination defects [21,22], and might be a consequence of the myelin deficiency 
observed in ASMKO mice [77]. On the other hand, it is clear that the composition of the 
hydrophobic moiety of a certain SL represents one of the factors that most deeply influence its 
ability to undergo lateral separation within a cellular membrane [84], thus affecting membrane 
lateral organization. Remarkably, this aspect of SL-mediated biology has been quite neglected in 
the past, and only recently the metabolic and cellular mechanisms responsible for the creation of 
the structural heterogeneity of the Cer moiety of cellular SL has been partially elucidated [85,86]. 
On one side, it resides in the specificity of Cer synthesis with regard of the fatty acid composition: 
at least six different Cer synthases contribute to the fatty acid heterogeneity of Cer in SL [85]. On 
the other hand, different transport mechanisms are responsible for the structure-selective 
delivery of Cer from the sites of synthesis to the sites of its metabolic utilization [86]. Thus, it can 
be expected that the influence of the structure of the hydrophobic moiety might be for a SL as 
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important as that of the hydrophilic headgroup. Indeed, it has been recently suggested that 
clustering of SL with C24 fatty acids might lead to the creation of quasi-crystalline structures in a 
liquid-ordered membrane matrix, thus providing an additional level of order within biological 
membranes [87]. On the other hand, it has been suggested that interdigitation of long fatty acid 
chains in SL might provide a physical and functional link between the inner and outer leaflet of the 
PM [88,89]. Thus, the significance of the alterations in SM composition hereby reported in 
ASMKO mice deserves further clarification 
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LYSOSOMAL STORAGE DISEASE and THERAPEUTIC TREATMENTS 
Biological macromolecule’s degradation, such as glycoproteins and glycolipids, takes places in 
lysosomes. Lysosomal enzymes, such as secretory and plasma membrane (PM) proteins, are 
synthesized in the endoplasmatic reticulum (ER), and most of them are transported to the Golgi 
apparatus and tagged for lysosome by the addiction of mannose-6-phosphate. The ER contains a 
highly retained mechanism to protect the cell from miss-folded and potentially toxic proteins, 
which is called endoplasmatic reticulum associated degradation (ERAD) pathway [1,2].  
The glycosphingolipidosis are a group of inherit disease that are caused by mutation in catabolic 
enzymes or their cofactors that reduce the efficiency of glycosphingolipid (GSLs) hydrolysis. This 
leads to a massive accumulation of GSLs in the lysosomes of affected cells. Lysosomal disorders 
differ from storage product, cells/tissue types affected, and severity. Pathology’s degree depends 
on the mutational impairment of catalytic activity. Most lysosomal storage disorders (LSDs) exist 
in infantile, juvenile and adult forms. The most severe LSDs, the infantile forms, show acute brain 
involvement and short lifespan. In adult forms, symptoms develop slower and disability often 
arises mainly from peripheral symptoms. Juvenile forms are intermediate between infantile and 
brainstem dysfunctions. In some diseases, phenotypic variability is explained by different levels of 
residual enzyme activity, but in others there is no obvious correlation between phenotype and 
genotype. Generally low levels of enzyme activity (<10%) predict that symptom onset occurs more 
rapidly, leading to infantile or juvenile disease.  
When the major site of accumulation is neural tissue, as in gangliosidosis (Sandhoff and Tay-sachs 
diseases), neurodegeneration is acute and often leads to premature death; whereas others have 
peripheral dysfunction without brain involvement (Fabry disease) [3-7]. 
Treatment of rare orphan diseases has received increasing interest despite their very low 
incidence. There are two fundamental approaches to reducing lysosomal storage of SLs in these 
disease: Enzyme Target Therapies (ETT), increasing the function of the lysosomes by restoring the 
deficient enzyme activity and Substrate Targeted Therapies (STT), reducing the substrate burden 
by inhibiting the synthesis of the SLs that cannot be degraded. The restoration of the defective 
lysosomal protein could be, in principle, achieved by different ways. i) Enzyme replacement 
therapy (ERT) that implies the direct delivery of the recombinant enzyme to the defective cells 
[8]. This approach presents problems related to the efficient targeting of the enzyme to the 
defective cells (especially within the nervous system), and to the stability of the delivered 
enzymes. However, it is currently used very effectively for the treatment of non-neurological 
(type 1) Gaucher and Fabry disease [9,10], and probably represents a valuable option for a non-
neurological (type B) Niemann Pick Disease (NPD) [11]. One of the major limitation of ERT 
                                                                                                                             
 
represents the blood-brain barrier that prevents the access of the intravenously administrated 
enzyme to the Central Nervous 
ex vivo Gene Terapy. Hematopoietic cells are able to cross the blood brain
therefore, used as vehicles for drugs and genes. After hematopoietic stem cell transplantation, 
donor derived cells migrate into the brain and differentiate to form microglia. An important 
principle of gene therapy for lysosomal diseases 
genetically corrected cell release enzymes that could be taken from neighbors cells. Nevertheless, 
at present, somatic gene therapy has led to variable results in animal models and faces difficulties 
in order to be approved for safety concerns
(e.g., β-glucosidase in an animal model of Gaucher
use of “Pharmacological chaperones”
[15], that will be discuss in details in the next section.
Alternatively to the restoration of the defective enzyme activity, it has further been suggested 
that the accumulation of undegraded substrates might be improved by inhibiti
(substrate reduction therapy). 
synthase [16,17], has been approved for the treatment of GD patients who cannot be treated with 
ERT [18]. It also has being used in patien
cholesterol metabolism) and some clinical neurological improvement has been noted
Regarding Tay-Sachs disease model mice
(NCT00672022) [20,21]. 
 
 
           Chaperone thera
System (CNS). ii) Another possible approach is represented by the 
is the phenomenon of cross
 [12-14]. iii) The reactivation of the defective enzyme 
 disease (GD)) has been also o
 (PC), small molecules directly interacting with the enzyme
 
N-butyl-deoxynojirimycin, an inhibitor of glucosylceramide (
ts with type C NPD (due to genetic abnormalities in 
, PC therapy is currently under clinical trial 
py for GM2 gangliosidosis 
100 
 barrier and can, 
-correction, where a 
btained by the 
 
ng their synthesis 
GlcCer) 
 [19]. 
 
                                                                                                                                        Chaperone therapy for GM2 gangliosidosis 
101 
 
Fig. 1 Therapies for lysosomal storage disorders. LSDs treatments can be divided into two fundamental 
approaches: one that directly modify the defective enzyme (grey) and other one that reduces the levels of 
biosynthesis of the accumulating substrate (blue) (Adapted from [4]). 
 
PHARMACOLOGICAL CHAPERONES 
Among all the causes that can lead to LSDs, one of them is represented by a genetic defect, a 
missense mutation, that often proves a destabilizing effect on the enzyme synthesis. These 
alterations lead to a decrease of termostability and not-correctly folded protein that is not able to 
retain the native fold and pass the ERAD. 
Enzymologists have long know that enzymes in the presence of a substrate or inhibitor are 
protected from thermo-denaturations.  
PCs are small molecules that can stabilize the conformation of mutant proteins, allowing them to 
pass the quality control system of ER (Figure 2). In this way the property folded mutant enzyme 
can be transported to the lysosome, increasing the residual enzyme activity of the cells [22-25].  
 
 
 
 
 
Fig. 2 Postulated molecular events between mutant enzyme molecules and chaperone compounds. 
Mutant enzyme protein is unstable in the ER-Golgi compartment at neutral pH, and rapidly degraded or 
aggregated possibly to cause ER stress. An appropriate substrate analogue inhibitor binds to misfolded 
mutant protein as pharmacological chaperone at the ER-Golgi compartment in somatic cells, resulting in 
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normal folding and formation of a stable complex at neutral pH. The protein-chaperone complex is safely 
transported to the lysosome. The complex is dissociated under the acidic condition and in the presence of 
excessive storage of the substrate. The mutant enzyme remains stabilized, and express catalytic function. 
The released chaperone is either secreted from the cell or recycled to interact with another mutant protein 
molecule. These molecular events have been partially clarified by analytical and morphological analyses, 
and computer-assisted prediction of molecular interactions (Adapted from [22]). 
 
It has been known since many years that the binding of an inhibitor to an enzyme stabilizes the 
enzyme: all successful PCs must be competitive inhibitors. Of course, we are talking about a 
reversible inhibitions: once the complex PC-enzyme reaches the lysosome, the stored substrates, 
that has a higher affinity with the enzyme then with PC, are able to displace the PC and take over 
the stabilization of the mutant enzymes [26,27]. 
Furthermore the chaperone affinity for the target protein should be regulated by the pH: the acid 
pH of lysosome reduces the affinity between the pharmacological chaperone and the enzyme 
[28,29]. 
Respect to the ERT, the PCs have the advantages to be orally administrated and to cross the 
blood brain barrier [28].   
PCs represent a very tractable therapeutic approach for a large proportion of genetic diseases 
where the point mutation do not totally prevent the formation of some functional 
enzyme/receptor (<2-5% residual activity) [29]. 
Given the general interest to apply the restoration of the defective lysosomal protein for a variety 
of late-onset of LSDs, the possibility to find suitable PCs could be a good approach. However, up 
to now, only five out of more than 40 LSDs have been targeted for this approach.  
For example one PC (AT1001, migalastat hydrochloride) is now being evaluated in phase II clinical 
trials for Fabry disease [30,31]. A further complication, based on the recent experiments with 
glucocerebrosidase (Gaucher disease), is that not all mutants with residual activity will be equally 
chaperoned by a single PC, and some were not enhanced at all [32]. This may be a significant issue 
for the LSDs that are not associated with a single or a few high frequency mutations.  
 
GM2 GANGLIOSIDOSIS 
Human β-hexosaminidase (β-hex) isoenzymes are glycosyl hydrolases that remove β-liked non 
reducing terminal GalNac or GlcNac from a number of macromolecules. There are two different 
subunits for β-hex, α (528 residues) and β (556 residues), that are encoded by two unlinked but 
evolutionary related genes, HEXA and HEXB. Each subunit has its own active site. However 
dimerization is necessary in order to became fully functional [1,33].  
                                                                                                                             
 
These subunits can form 3 different 
 
Hex A (αβ),  
Hex B (ββ),  
Hex S (αα).  
The Hex S isoform is unstable and it is only detectable in Sandhoff patients. 
 
 
Fig. 3 β-hexosaminidase isoforms
 
The active site of the β-subunit hydrolyzes uncharged substrates, whereas the α
addiction cleaves the negatively charged substrates. Only the αβ heterodimer HexA is able to 
degrade ganglioside GM2 producing GM3 ganglioside, in presence of GM2 activator protein, a 
specific co-factor for Hex A [34]
 
 
 
Fig. 4 Model of GM2-activator-
binding site is lined by two hydrophobic
most flexible of the loops (V153
open and closed conformation.
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stimulated hydrolysis of ganglioside GM2 by human
 (V90-W94 and V153-L163) surface loops and
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Genetic defect in either the gene encoding the subunits of Hex A (αβ) can result in accumulation 
of GM2 in neural tissue leading at two of th
(defect in α subunits) and Sandhoff disease (defect in β subunits). The third form of the disease, 
the AB variant, is caused by a deficiency of the GM2 activator protein. 
Mutations that cause a comple
with these forms of the disease usually die before they reach the age of four. Mutation that 
affects folding or dimerization, but compatible with the formation of some functional enzyme, 
resulting in residual Hex A activity (1
clinical phenotype. It has been estimated by Sandoff and 
between 5-10% of normal is enough to prevent the GM2 accumulation
 
Use of pharmacological chaperones: the PYRIMETHAMINE
To the best of our knowledge, to date, there is no cure for the treatment of GM2 gangliosidosis.
Several molecules that act as inhibitors of Hex A and Hex B have been identified as a potential 
for late-onset GM2 gangliosidosis, including known inhibitors of Hex, like the N
thiazoline (NGT), a sulfur analogue of the oxazolinium ion intermediate, formed during substrate 
turnover (Ki 300 nM) [1,35] . 
Recently, the group of Maur
pyrimidinediamine] as PC for the treatment of the late onset form of Tay
(Figure 5). 
 
 
Fig. 5 Pyrimethamine’s structure.
 
PYR is an anti-malarial drug already appr
Specifically, it binds the active site of dihydrofolate reductase (DHFR), preventing substrate 
access [1,36].  
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te enzyme deficiency are extremely severe, and children affected 
-5% of normal) are less severe and results in a “late onset” 
colleagues that a residual activity 
 [3, 29]
 
an has identified pyrimethamine [PYR, 5-(4-chlorophenyl)
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In the structure of Plasmodium vivax DHFR, PYR is located in a deep pocket containing the 
catalytic residues. The p-chlorophenyl ring makes van der Waals contact with the DHFR cofactor 
NADPH [36].  
Bateman and collaborators [1] showed that PYR also binds the active site in the structure of HexB. 
Although the active site of HexB appears shallower than DHFR, there are many similarities to 
DHFR in binding the drug. The pyrimidine ring stacks against an aromatic residue and forms 
similar hydrogen bonding interactions with residues belonging to the active site. 
Even thought, the crystal structure of HexA was difficult to obtain in comparison of HexB, so 
Bateman’s group made a superimposition of the active site residues in the structure of HexB:PYR, 
suggesting that a HexA:PYR interaction could be closely resemble that of HexB:PYR [1] 
The binding of PYR to the active site of HexB introduces five hydrogen bonds per active site and 
several favorable van der Waals contacts. Potentially PYR increases the stability of the protein 
fold and develops the correct conformation for the active site [1].  
One important characteristic of the PYR is the pH sensibility. NGT inhibits Hex A activity at pH 4.5, 
whereas PYR has an optimal inhibitory profile at pH of 6.5. Thus, PYR inhibits best at the internal 
pH of the lumen of ER where a chaperone is needed to assist mutant Hex subunits in their folding, 
to permit to escape the ERAD control.  Once in the lysosome, due to the lowest pH, the PYR 
affinity for the enzyme decrease and the enzyme could be available for substrate and thus 
stabilized [29,37]. 
Mauran and colleagues showed that the PYR is more effective than NGF to increase the activity of 
β-hex. They also show that PYR is able to increase the hydrolysis of both natural and artificial 
substrate for β-hex [1,29,37,38,40].  
All the data published until now said that PYR is able to increase the folding stability of both 
subunit α and β, stabilizing the mutant enzymes sufficiently to allow more β-Hex to arrive to the 
lysosomes [1,29,37-,40]. Mauran and collegues showed that PYR is able to increase the activity of 
Hex A, the only isoform ables to hydrolyze GM2 [1,29,37,38,40]. 
One of the limits in the use of this treatment is that the mutations of β-hex gene should not 
related to the active site of Hex A and Hex B, the binding site of PYR (Table I). If so PYR is not able 
to sit in the active site and to stabilize the miss-folded protein. Since most of the destabilizing 
mutations are not in the immediate vicinity of the active site, they will not interfere with PYR 
binding. In vitro studies have shown that many mutations in either the α and β subunit of Hex A 
can be partially recovered, enhancing the levels of Hex A activity in lysosomes, following the 
growth of the patients cells in the presence of the PYR (Table I) [1,37,38].  
Only last year has been started a clinical trial for the treatment of patients affected by cronic GM2 
gangliosidosis, with the aim to establish the efficacy of the treatment with PYR [37]. 
                                                                                                                             
 
It’s important to note that one of the other reason for the success of PYR, as an antimalarial and 
potential PC candidate, is that PYR does not seriously harm the function of human DHFR 
We also have to report that the treatment with PYR have several adverse effects, that must be 
considered in an overall perspective of the t
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Several approaches are available to assay the activity of Hex A: i) The classic one is the use of 
natural or radiolabeled substrate [41,42] ii) The  use of synthetic substrates. MUG is the simplest 
assay in use. It is hydrolyzed by both the α and β active sites and therefore is used to measure 
total Hex activity and MUGS, a recent more specific substrate, negatively charged, that reacts 
only with α subunits. MUGS is activator independent and it is used to measure activity from Hex A 
and Hex S [40,42]. 
We perfectly know that assaying Hex A enzymatic activity towards its natural/or radio-labelled 
substrate is today quite impractical due to the high amount of Hex A activity (purified enzyme), to 
the difficulty to obtain and use the radio compound as natural compound and to the high cost of 
these type of research. 
Artificial substrates are used to diagnose GM2 gangliosidosis and to determine the efficacy of 
therapy with different approach, as routine [40].  
With this project we want to demonstrate the need to continue to use the classical biochemical 
approach, especially in the early stages of validation of the new therapy. 
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MATERIALS 
Commercial chemicals were of the highst purity available, common solvents were distilled before 
use and water was doubly distilled in a glass apparatus. Trypsin, reagent for cell culture , 
Condutirol B Epoxide (CBE), 4-Methylumbelliferyl-β-N-acetylglucosaminide (MUG) and 
Pyrimethamine were from Sigma-Aldrich (St. Louise, MO, USA). Minimum Essential Medium with 
Earle’s Salt (MEM) and fetal calf serum were purchased from EuroClone (Leeds, UK).  
GM1 and GM2 was prepared by sialidase digestion of a bovine brain ganglioside mixture and 
purified (Acquotti et al. 1994). [3-3H(sphingosine)]GM1 (specific radioactivity, 2.3 Ci/mmole) used 
as substrates of enzymatic assays and as chromatographic standards were prepared as described 
(228). Highperformance silica gel thin-layer plates (HPTLC Kieselgel 60, 10 x10 cm) were purchased 
from Merck GmbH (Milan, Italy). AM-calcein was from Invitrogen (Carlsbad, CA, USA). Triton X-100 
were from Merck (Darmstadt, Germany). 4-Methylumbelliferyl-β-N-D-galactopyranoside (MUB-
Gal). 4- Methylumbelliferyl-β-N-acetylglucosaminide-6-sulphate (MUGS) was from Toronto 
Research Chemicals Inc. (North York, Ontario, CDN). 
 
METHODS 
 
Cell Cultured 
Primary skin fibroblast from unaffected and affected patients were obtained by the punch 
technique, cultured and propagated as described [43], using Minimum Essential Medium with 
Earle’s Salt (MEM) supplemented with 10% FBS, 1% Glutamine and 1% Penicilin/Streptomicin. The 
cells were cultivated as monolayer in a humidified atmosphere at 37°C and 5% CO2. 
 
Cell Viability  
Cell viability was assessed by calcein staining [44]. Cells were washed with PBS, the plate was 
then put on ice and 200 μl of calcein-Am solution (6.25 μg/ml in PBS) were added to esch well. 
Cells were incubated for 15 min at 37°C, 5% CO2. Calcein-AM was then removed and 100 μl of PBS 
and 50 μl of 1% Triton-X100  were added to esch well. Plate was strirred at RT for 15 min and then 
the fluorescence was detected by a microplate reader (Victor, Perkin-Elmer). 
 
Treatment of cell cultures with PYR 
SD and control fibroblast were treated with PYR (dissolved in Ethanol, final concentration 
1μg/mL) or with Ethanol (as control), for 72h [38]. 
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Treatment of cell cultures with [3-3H(sphingosine)] GM1 
[3H] GM1, dissolved in propan-1-ol/water, 7:3 (v/v),  was transferred into a sterile glass tube, and 
dried under nitrogen stream; the residue was then solubilized in an appropriate volume of pre-
warmed cell medium (serum free) to obtain the desired final concentration (….M). After 18h 
incubation (pulse) in presence of GM2 (5μg/ml) and CBE (50 μM), cells were washed and 
incubated 2h (chase) with cell medium not containing radioactive ganglioside [40,41].  
 
Radioactive lipid analyses 
Cells were lyophilized and subjected to lipid extraction and SLs analysis. Total lipids from 
lyophilised cells were extracted with chloroform/methanol/water 20:10:1 by vol. followed by 
chloroform/methanol 2:1 by vol. The total lipid extracts were subjected to a two-phase 
partitioning by adding 20 % water to the lipid extract; the total lipid extract, the aqueous and 
organic phases were analyzed by HPTLC (1000 dpm/lane). [3H]SLs of total extracts and organic 
phases were separated using the solvent system chloroform-methanol–water 110:40:6 by vol, and 
those of aqueous phases with chloroform-methanol-0.2 % aqueous CaCl2, 50:42:11 by vol. 
[3H]SLs were identified by referring to the position of standards in the chromatogram and 
quantified by radioimaging after 48–96h of acquisition (β-Imager 2000, Biospace, Paris, France) . 
 
Enzymatic activities of cell lysates 
The enzymatic activities associated with total cell lysates were determined using fluorigenic 
substrates as described previously  with some modifications [45,46]. Briefly, cells were washed 
twice with PBS, harvested, and resuspended in water in the presence of a protease inhibitor 
cocktail (Roche). Aliquots of the cell homogenates were transferred to a 96-well microplate and 
enzymatic assays performed with five-fold replication. MUB substrates were solubilized in 
McIlvaine buffer at the opportune final concentration and  opportune pH for each enzyme. The 
reaction mixtures were incubated at 37°C with gentle shaking. The developed fluorescence was 
detected at various times by a Victor microplate reader (Perkin Elmer) after transferring 10 μl of 
the reaction mixtures to a microplate and adding 190 μl of 0.25 M glycine, pH 10.7. The data were 
expressed as nmoles converted substrate/ 106 cells/ hr. 
 
β-hexosaminidase activity 
β-hex activities were determinate using the 4-methylumbelliferyl derivates of either β-N-
acetylglucosaminide (MUG) or β-N-acetylglucosamine-6-sulfate (MUGS). MUG was solubilized at 
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final concentration of 3mM in Mcllvaine Buffer (0.1M Citrate/0.2 Phosphate) pH 5.0. MUGS was 
solubilized at final concentration of 1mM in Mcllvaine Buffer (0.1M Citrate/0.2 Phosphate) pH 5.0 
 
β-galactosidase activity 
β-Gal activity was determinate using MUB-Gal, solubilized at the concentration of 0.25mM in 
Mcllavine Buffer (0.1M Citrate/0.2 Phosphate) pH 4.0. 
 
β-hexosaminidase isoenzymes analysis (DEAE Column) 
Cell lysates were analyzed by the ion-exchange chromatography on DEAE-cellulose [41]. The 
chromatography was performed by using 1-ml column equilibrated with 10 mM sodium phosphate 
buffer, pH 6.0 (buffer A). the flow rate was 0.5ml/min. proteins retained by the column were 
eluted using a linear gradient of NaCl (0.0-0.5 M in 40ml of buffer A) and then eluted with 1.0 M 
NaCl in the same buffer. Fraction (1ml) were collected and assayed for the Hex activity with the 
two substrates, MUG and MUGS. 
 
Other analytical methods 
The radioactivity associated with lipid extracts was determined by liquid scintillation counting. 
Digital autoradiografy of HPLC plates was performed with a Beta-Imager 2000 Instrument 
(Biospace, Paris). The radioactivity associated with individual lipids was determinate with the 
specific B-Vision software provided by Biospace. 
The protein assays were carried out using the DC protein assay in according to manufactures 
instructions (Biorad). 
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Here we report the treatment with PYR of two cell lines (fibroblast) derived from two patient, 
displacing two new mutations for Juvenile Sandhoff disease, #1 and #2. 
Complete sequencing of the HEXB gene showed that patient #1 carried the common 16 kb 
deletion (including promoter and exons 1-5) on one allele and a novel splice mutation in intron 2 
(c.446-13A>G) on the other allele [48]. Patient #2 was homozygous for a previously reported 
mutation (c.1082+5G>A) present in intron 8 [49].    
Their clinical phenotype was characterized by progressive hypotonia, seizures, exaggerated 
reaction to sounds and presence of a cherry-red spot at the ophthalmoscopic examination. 
Biological diagnosis was performed on leukocytes and serum by using enzymatic tests based on 
the 4-methylumbelliferyl derivatives of β-N-acetylglucosaminide (MUG) or β-N-acetylglucosamine-
6-sulfate (MUGS), permitting to evaluate the activity of total hexosaminidases or specific 
hexosaminidase A, respectively. Both patients had an hexosaminidases A and B deficiency 
confirming the diagnosis of Sandhoff disease or GM2 gangliosidosis variant 0.  
Cultured fibroblasts were obtained from both patients and β-hexosaminidase activities were 
measured with the artificial substrates MUG and MUGS [28,39]. Both patients showed a residual 
β-hexosaminidase A activity around 2% with the MUGS substrate, leading the possibility for them 
to be candidate for an enhancement enzyme therapy [3,29]. 
 
i. Preliminary experiments 
We have designed a set of preliminary experiments focused to test the concentration of PYR to 
use and the PYR toxicity. 
As control cells we use fibroblast form healthy subjects. The cells not treated with PYR where 
incubated always in the presence of ethanol, the solvent of PYR. 
 
PYR concentrations 
As primary step we tried different concentration of PYR to see the effect on Hex-activity  (0.5-10 
μg/ml of cell cultured medium).  We observed a maximal effect at concentration of 1 μg/ml of cell 
cultured medium and we noticed that the increase of activity is not dose-dependent (Table II).  
 
Cell Viability 
To investigate the toxicity of PYR on cell viability we performed the Calcein analysis. The 
treatment with PYR for 24, 48, 72 and 96 h do not alter cell viability and death, compared with 
control cell. For further experiments we fix at 72h the period of incubation (Figure 6). 
 
 
                                                                                                                             
 
Table II PYR concentration. 
PYR concentration is expressed as μg of PYR/ ml of cultured media. MUG and MUGS are representative of 
the substrate hydrolysis (expressed as arbitrary units of fluorescence). % of  activity is respect to the CTRL 
cells (fibroblast from health donor)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Cell viability (1, untreated cells; 2, treated cells) Ctrl= control cells incubated with Ethanol; #1: cell line 
#1; #2: cell line 2. 
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ii. PYR increase the β-Hex activity using the MUG and MUGS substrates.
To understand if the two fib
treatment, we assesed the β
lysate after 72h of treatment with PYR (1 μg/ml).
The total Hex activity (MUG) showed no signific
was used like substrate, it showed a  significant increase in subunit α activity. On the contrary 
treated #2 cells showed a significant increase in both MUG and MUGS substrates.
Both #1 and #2 fibroblasts, 
measured with artificial substrate MUGS
 
 
Fig. 7 β-Hex activity (1, untreated cells; 2, treated cells) Ctrl
#1; #2: cell line 2. 
 
 
iii. PYR does not increase other
We also evaluated the PYR’s effect on other glycohydr
(β-gal). PYR had no effect on the activity of β
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t (Figure 8). 
                                                                                                                             
 
 
Fig. 8 β-Gal Activity (1, untreated cells; 2, treated cells) Ctrl
#1; #2: cell line 2. 
 
iv. PYR does not increase the β
To confirm the capacity of PYR to increase the activity of β
isotopically tritium labeled GM1 ganglioside, which is the lysosomal precursor of GM2. After 72h of 
treatment with PYR, GM1 was added to FBS
chased  for 2h with fresh FBS
To reach the same gangliosides concentrations of neurons, we also performed an experiment in 
the presence of natural GM2 (50 μM) and in the presence of CBE, a non reversible inhibitor of 
glucocerebrosidase 2, to stop the degradation pathway of GM2 at GlcCer step.
The cells were then subjected to lipid extraction. The total radioactive lipid extracts were 
analyzed by HPTLC. In both control and 
GM2, indicating that GM1 administered to cells was taken up by the cells and reached the 
lysosomes. In control cells GM2 was transformed into GM3 as indication of the correct lysosomal 
SL catabolism. As expected, in Sandhoff cells no GM3 was produced due to 
Surprisingly, and in contrast with the increased activity of 
could not see any transformation of GM2 to GM3 (and reduction of GM2) in 
cells (Figure 9). 
 
v. PYR increase the activi
Then we tried to understand if the observed increase of the activity consequent to artificial 
substrates administration could be an artifact or not. 
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β-hex chain β.  
PYR treated Sandhoff 
-Hex isoforms 
                                                                                                                             
 
To better investigate the β-
isoforms (B, A and S) of β-hex, by DEAE column chromatography
Separation of β-hex isoforms [41] and determination of their activity showed that the residual 
activity of Sandhoff fibroblasts is due essentiall
activity (Fig. 2). Hex S enzyme recognizes the artificial substrates but not ganglioside GM2. No 
effect on the β-hex A was observed. 
  
 
 
 
Fig. 9 Cultures of control fibroblasts and Sandhoff fibroblasts w
Sph]GM1 [40] and treated with PYR (1, untreated cells; 2, treated cells)
partitionated and gangliosides were separated on HPTLC using the solvent system 
chloroform/methanol/0.2% calcium chlori
visualized by digital autoradiography.
administered to cells was taken up by the cells, reached the lysosoms where the 
transformed GM1 into GM2, by detachment of the external galactose. In control cells, fibroblasts from 
healthy donors, the formed ganglioside GM2 was transformed into GM3 by 
treated Sandhoff cells (both cell 
ineffectiveness of PYR. We confirmed the inhibitory activity of 
accumulation of GM2 [28], as suggested by the reduced production of GM3 in control cells.
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Fig. 10  Analysis of β-hex isoform pattern
DEAE-cellulose column chromatography using a NaCl gradient as eluting system. 
unretained by the column and eluted with the void
isoforms (Hex S, αα-dimer) were eluted by the linear saline grad
of 1 ml were collected and assayed for 
hydrolyzed by β-hex isoforms A, B and S, and MUGS, which is hydrolyzed by the isoforms A and and S. The 
same amount of proteins for each sample was loaded on the colum
           Chaperone thera
. β-hex isoenzyme separation was performed by ion exchange 
 volume, whereas β-hex A (αβ
ient as previously described [41]
β-hex activity using the fluorescent substrates MUG, whi
.  
py for GM2 gangliosidosis 
119 
 
β-hex B (ββ-dimer) was 
-dimer) and other β-hex 
. Fractions 
ch is 
                                                                                                                                        Chaperone therapy for GM2 gangliosidosis 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                        Chaperone therapy for GM2 gangliosidosis 
121 
 
Sandhoff disease is an autosomal recessive neurodegenerative disease characterized by 
the intralysosomal accumulation of GM2 ganglioside. It is due to mutations in the β-hexs 
β-chain gene, resulting in a β-hexs A (αβ) and B (ββ) deficiency. Several β-chain gene 
mutations have been described. This disease predominantly affects the central nervous 
system and has a dramatic evolution [47]. 
Lysosomal enzymes are synthesized in the endoplasmic reticulum, and most of them are  
transported to the Golgi apparatus for glycosylation and tagged for lysosomes, by the 
addition of mannose-6-phosphate. The ER contains a highly conserved degradation 
pathway to protect cells from misfoldingand potentially toxic proteins. Thus, the protein 
turnover ensures integrity and biological functions of cells [29,40]. 
Treatment of sphingolipidoses, such as Sandhoff disease, have received increasing 
interest despite the low incidence. Replacing enzyme therapy meets the problem to be 
ineffective over the blood brain barrier and new approaches are now under investigation. 
One of the possible approach is the use of pharmacological chaperones. Pyrimethamine, 
a drug used to treat or prevent serious parasite infections such as toxoplasmosis and 
malaria, has been described to act as chaperone for the β-hex [29,39,47]. As chaperone 
PYR stabilizes the conformation of mutated protein, it allows the missfolded proteins  to 
pass the quality control system of ER. Thereby, the stable folded protein can be 
transported in higher quantity to lysosomes, increasing the residual enzyme activity. 
Pharmacological chaperones that give better results are also competitive inhibitors: 
inhibition must be reversible by the large amount of substrate accumulated in lysosomes. 
Furthermore the PYR affinity for the β-hex is regulated by the pH: the acid pH of lysosome 
reduces the affinity between the pharmacological chaperone and the enzyme [28,29]. 
Nevertheless, the effectiveness as chaperone of PYR occurs as a function of the 
conformation of the mutated protein interacting with the chaperone, and not all the 
mutations on the β-chain allow the protein to interact with PYR.  
Here we reported the treatment of two cases of juvenile Sandhoff disease [47], 
displaying the new mutations C1082+5G>A (#1) and C446-13A>G (#2) in the HEX B gene 
with PYR. The drug, when administered to Sandhoff patients, is believed to increase β-
hex expression and activity and to reduce GM2 lysosomal accumulation. The effects of 
PYR have been tested on cells carrying several different mutations, but not all responded 
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as expected. The drug causes also serious adverse effects [39] and should be used only 
after verifying its effectiveness.  
The two examined cell lines, after treatment with PYR showed an increased total β-hex 
activity, so that the residual value was around 10%. This value should be enough to limit 
the accumulation of GM2 [41]. In contrast to this, cells treated with PYR and fed with 
isotopically tritium labeled ganglioside GM1 did not show any GM2 lysosomal catabolism. 
This negative result was explained after fractionation of the total cell proteins by ion 
exchange DEAE column chromatography. Clearly, we found that the increased β-hex 
activity on the artificial substrate was due to the  increase of the activity of β-hex isoform 
S. Unlikely, the isoform S, even if it hydrolyzes the artificial compound, does not 
recognize the natural substrate GM2 and therefore the PYR is unable to modify cell 
lysosomal activity in the two cell lines showing the new mutations C1082+5G>A and C446-
13A>G  and moreover cannot be used as a therapeutic drug for the two patients. 
These results suggest that analysis of the enzymatic features of the β-hex isoforms of 
patient’s fibroblasts and the feeding experiments with tritium labeled gangliosides are 
very useful to determine the effectiveness of the chaperone PYR. These clinical chemistry 
investigations give a valuable information to decide on the therapeutic use of PYR: our 
results are in agreement with a previous information on the selective activity of PYR 
depending on the mutation [29,39,47] and confirm the advantages deriving from the 
investment of patients’ fibroblasts for the decision on the use of PYR as therapeutic drug.  
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GLYCOHYDROLASES 
Glycohydrolases are a widespread group of enzymes involved in glycosphingolipids (GSLs) 
metabolism, that hydrolyse the glycosidic bonds. The glycohydrolases are ubiquitous enzymes, 
being found in lysosomes, plasma membranes (PM), cytosol and blood plasma [1-5]. 
Glycohydrolases are found in essentially all domains of life. In bacteria and prokaryotes, they are 
found both as intracellular and extracellular enzymes largely involved in nutrient acquisition. One 
of the important occurrences of glycohydrolases in bacteria is the enzyme β-galactosidase (LacZ), 
which is involved in regulation of expression of the Lac-operon in Escherichia Coli. In higher 
organisms glycohydrolases are found within the endoplasmic reticulum (ER) and Golgi apparatus 
where they are involved in processing of N-linked glycoproteins, and in the lysosomes as enzymes 
involved in the degradation of carbohydrate structures. Deficiency in specific lysosomal 
glycohydrolases can lead to a range of lysosomal storage disorders that result in developmental 
problems or death.  
 
THE REGULATION OF GSLs COMPOSITION AT THE LEVEL of PM 
Changes in the GSLs composition of the PM in a certain cell type would lead to very important 
biological consequences, thus all mechanisms possibly contributing to these changes have a high 
functional significance. The classical view on sphingolipid (SL) metabolism implies the vescicular 
transport of neo-biosynthesized SLs from the ER and the Golgi apparatus to the PM (reviewed in 
[6]). Changes in the activities of enzymes of the biosynthetic pathway have been associated with 
the changes in GSLs expression that are correlated with biological events such as neoplastic 
transformation or neuronal differentiation. However, other mechanisms could be responsible for 
a local regulation of the GSLs composition of PM on restricted PM areas (Figure 1): 
i. Both catabolic and biosynthetic enzymes for SLs have been found associated with the PMs. 
“Signaling” sphingomyelinases (SMase) are resident in, or translocated to, the PM, being able to 
convert PM sphingomyelin (SM) into ceramide (Cer) [7,8]. Conversely, a PM-associated SM 
synthase enzyme activity (SMS2), genetically distinct from the Golgi enzyme, has been identified 
[9]. Thus, the SM/Cer ratio can be locally modulated possibly in response to physiological events, 
leading to profound consequence on the organization of SLs-enriched membrane areas. In the 
case of GSLs, a specific PM associated sialidase (Neu3) has been identified and cloned [10,11,12], 
and its role in modifying the ganglioside composition at the cell surface, acting as well on GSLs 
molecules present on the surface of adjacent cells (i.e., in a “trans” fashion), has been proven 
[13,14,15].  
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Fig. 1 Regulation of SLs-enriched membrane domains composition by phosphorylation/dephosphorylation 
(“SM cycle”) and glycosylation/deglycosylation. 
 
Moreover, the presence of sialyltransferase activities at the cell surface has been also reported 
[16-20].  For example, it was recently reported the presence CMP-NeuAc:GM3 sialyltransferase 
(Sial-T2), that is able to sialylate GM3 at the PM (cis-catalytic activity) by using both the exogenous 
and endogenous donor (CMP-NeuAc) and acceptor (GM3) substrates [21]. Thus, 
glycosylation/deglycosylation cycles might be very important mechanisms responsible for rapid 
and possibly transient changes of the PM-GSLs composition, in analogy to that proposed for the 
“SM cycle” (Figure 1). The presence of other active glycohydrolases such as β-glucosidase (β-Glc), 
β-galactosidase (β-Gal) and β-hexosaminidase (β-Hex) [13,22] in the PM has been demonstrated, 
implying that local hydrolysis of GSLs at the cell surface might represent a general mechanism for 
the control of GSLs composition.  
ii. GSLs can be released from the cell surface in different forms, including shedding vesicles [23-
25], whose controlled release from specific glycolipid-enriched membrane areas could represent a 
further way to modify the lipid membrane domain composition and organization. 
                                                                                                               Sphingolipids glycohydrolases during tumor irradiation 
132 
 
MEMBRANE GLYCOHYDROLASES 
PM glycoconjugates show changes during development and neoplastic transformation [26,27] 
suggesting a specific role in cell–cell recognition. Glycosyl epitope changes include many different 
residues, such as GlcNAc, GalNAc in N-linked structures or sialyl residues in either protein N-linked, 
O-linked or lipid linked structures, so that cell surface glycohydrolases could be one of the natural 
candidate for PM glycosylation modification.  
For this reason, although in the past little attention was paid to glycohydrolases acting on cellular 
compartment different from lysosomes, there is now increasing interest on PM associated 
glycohydrolases: in this compartment they can be involved, together with glycosyltransferases, in 
GSLs oligosaccharide modification processes regulating cell to cell and/or cell–environment 
interactions in both physiological and pathological mechanisms [15,28,29] . 
Glycohydrolases are the enzymes involved in GSLs metabolism. The presence of glycohydrolases 
on the PM, where they can be involved in the modifications of the cell surface GSLs or of 
glycoproteins, has been demonstrated [30]. This class of enzymes are taken into account as they 
can participate in the modulation of signal transduction processes.  
Some of the PM associated glycohydrolases are identified and their activity has been studied for 
characterization. They are: 
 β-Hexosaminidase 
 Sialidase  
 β-galactosidase 
 β-glucosidase 
 Sphingomyelinase 
The presence of β-Hex A (Figure 2) in the external leaflet of PM has been demonstrated in 
cultured fibroblasts [22]. Immunological and biochemical characterization of the membrane-
associated β-Hex indicated that this enzyme has the same structure of that in lysosomes.  
 
 
Fig.2 Reaction catalyzed by β-Hex A. 
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The linkage of sialic acid in sialic acid containing molecules is hydrolyzed by several different 
sialidases (Figure 3). Taking in account all the available data, Neu3 can be considered an 
ubiquitous enzyme being expressed at different levels in all the PM of tested normal and 
pathological human tissues such as human brain [31] normal and colon rectal carcinoma tissue, 
hepatic tumor and kidney carcinoma [32-36]. In addition its expression and activity were also 
found in normal and pathological cell lines such as erytroid and erytroleukemic cells [37-39], 
human fibroblasts [40], rat and mouse neurons, neuroblastoma cells [41], human breast ductal 
cancer T47D cells, colon carcinoma CaCo2 cells, human colorectal adenocarcinoma HT29 cells, 
different type of ovarian cancer cells, human cervix adenocarcinoma HeLa cells [36]. It has been 
demonstrated the presence of Neu3 in the lipid rafts and its co-localization with gangliosides: the 
non-random distribution of Neu3 at the cellular surface introduces the possibility that the 
biological effects of this enzyme might be due to the local reorganization of GSLs-based signaling 
units. Remarkably, Neu3 is capable to modulate the cell surface glycolipid composition because of 
trans interactions, thus modifying the surface of neighboring cells [15]. 
 
 
Fig.3 Reaction catalyzed by sialidase. 
 
PM associated β-Gal (Figure 4) has been found in all cell lines studied for the activity of Neu3. In 
human fibroblasts its expression is up regulated by Neu3 [13]. The β-Gal activity was measured 
during neuronal cell differentiation and aging, in the total cell lysate and in the PM from rat 
cerebellar granule cells. 
Both these activities resulted up regulated during cell differentiation. As expected the β-Gal 
activity associated to the cell PMs was much less than that found in total cell homogenate. The 
total cell activity remained constant during differentiation, then increased 4 fold along aging in 
culture. Instead, cell surface activity increased 10 fold during differentiation, to then duplicate 
during the neuronal senescence [42]. β-Gal activity has been proposed as senescent marker of 
different cell lines [43-46]. The information on the behavior of PM associated enzyme in rat 
cerebellar granule cells suggests that its activity could be used as a good marker for both 
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neuronal differentiation and neuronal aging. The identity of the protein, or proteins, responsible 
for the β-Gal activity present at the cell surface is still unknown, however in living human 
fibroblasts has been verified the presence of a β-Gal activity which displays a trans activity, with 
no necessity of detergents or activator proteins, on lactosylceramide (LacCer) immobilized on cell 
culture plates, suggesting that on the cell surface is present at least an enzyme having a β-
galactocerebrosidase-like activity [30]. 
 
 
Fig.4 Reaction catalyzed by β-Gal. 
 
Concerning β-Glc (Figure 5), at least three different enzymes have been described: a β-
glucocerebrosidase sensitive to the inhibition of Conduritol B Epoxide (CBE) normally described 
associated to the lysosomes [47], a cytosolic β-Glc [48] and a non-lysosomal β-glucosylceramidase 
(GBA2). GBA2 has been found associated to endosome vescicles or to the PM, it is insensitive to 
CBE whereas is specifically inhibited by N-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin 
(AMP-DNM) [49,50]. Recently it has been described that a CBE-sensitive β-Glc activity is present in 
the PMs [30]. Both CBE-sensitive and CBE-insensitive β-Glc activities were found associated to the 
cell surface of rat cerebellar granule cells in culture, where they progressively increase along the 
differentiation and the aging process [42]. 
Total β-Glc activity associated to the PMs of human living fibroblasts works on natural substrates 
in trans fashion [30] and the activity is connected to Neu3 activity. In fact, in human fibroblasts 
over-expressing Neu3, the β-Glc activity associated to the PM was much higher of that found in 
normal fibroblasts. Surprisingly this is mainly due to an up-regulation of the CBE-sensitive β-
glucosidase [30].  
                                                                                                               Sphingolipids glycohydrolases during tumor irradiation 
135 
 
 
Fig.5 Reaction catalyzed by β-Glc. 
 
Three different SMases are available in eukaryotic cells [51]: secreted SMase, acid SMase and 
neutral SMase (nSMase). Secreted SMase exerts its activity in the extracellular environment. Acid 
SMase are principally located in the lysosomes and few evidences reports about its association to 
PM. Neutral SMase identify a family of different enzymes that catalyze the hydrolysis of SM into 
Cer at pH 7.4 and are Mg2+-dependent enzymes. Among the three recently cloned mammalian 
neutral SMases, only nSMase2 and nSMase3 display in vivo activity. nSMase3 is reported to 
localize to the endoplasmic reticulum and the Golgi compartment [52,53] while the subcellular 
localization of nSMase2 remains not fully determined. nSMase2 was first described as a Golgi-
associated protein potentially involved in the Golgi secretory vesicle trafficking [54], however 
other studies have indicated a PM localization of overexpressed GFP-, FLAG- or V5-tagged-
nSMase2 in various cancer cell lines [55-57]. This enzyme is characterized by the presence of two 
palmitoylation sites that were reported to be important for PM localization [58]. Furthermore, 
stimuli such as TNFα, H202 and cell confluence seemed  to induce nSMase2 translocation from the 
Golgi to PM lipid rafts [51]. 
Therefore the glycol-hydrolytic enzymes, responsible for the catabolism of the SLs, are not only 
recovered in the classical cellular compartment deputed to the catabolism (the lysosomes) but 
are also associated to other cellular district. In some case the same lysosomal enzyme has been 
found associated to other compartments, as is the case of the β-Hex A associated to the PM; in 
some others, enzymes codified by different genes have been found in different regions of the 
cell. This last is the case of the sialidases Neu2, Neu3 and Neu4 with respect to the lysosomal 
enzyme Neu1, or the case of the non-lysosomal β-glucosylceramidase GBA2.  
Considering the presence of lysosomal glycohydrolases at the cell surface, two aspects need to be 
clarified: how lysosomal deriving enzymes can reach the PM and how they can be active at the cell 
surface where the pH conditions are far from those of the lysosomes? It is known that a regulated 
fusion of lysosomes with the PM might represent a general mechanism of repairing for the PM 
[59], and could be responsible of the presence of lysosomal enzymes facing at the cell surface. 
However this enzymatic “translocation” could not be accidental and the fusion of lysosomal 
membranes with the PM could be the way for all the lysosomal glycolipid-metabolizing enzymes 
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to reach the cell surface where, together with specific and different membrane associated 
enzymes, play an active role in remodeling the glycolipid content and pattern of the external 
leaflet of the PM.  
At the cell surface the pH conditions are usually considered near to the neutrality, whereas the 
lysosomal pH is much more acidic. For some glycohydrolases described associated to the PM has 
been evaluated the optimum of pH to which they play their catalytic activity. Both the β-Hex A 
and Neu3 (respectively codified by the same and by a different gene with respect to the 
corresponding lysosomal enzyme) has been found working in acidic condition (pH 4.45 and pH 4.2 
respectively). This information suggests that modulation systems, capable to modify the pH 
conditions, even locally, could be present at the cell surface. One hypothesis for this theory may 
be the action of proton pumps present at the PM level for which has already been demonstrated 
a role in the acidification of the tumor extracellular environment [60-62]. 
 
GLYCOSYLATION and CANCER MALIGNANCY 
Aberrant glycosylation, at the cell surface level, has been observed in essentially all type of human 
cancer. This event contributes to deep alterations in the interactions between tumor cells and the 
extracellular environment, which underline many of the features that defined several tumor 
phenotype, including self-sufficiency in growth signals, insensitivity to growth-inhibitor stimuli, 
evasion from programmed cell death (apoptosis), sustained angiogenesis, and tissue invasion and 
metastasis (Figure 6) [27] 
Alteration in glycan expression in cancer is usually a consequence of modification in the metabolic 
pathway of glycoconjugates, as a result of change in the biosynthesis, catabolism and intracellular 
trafficking of GSLs and glycoproteins.  
Like reported above, changes of the glycoconjugate oligosaccharide structures and in particular 
changes of GSLs, can be obtained at the cell surface by the activities of PM-glycohydrolases.  
Recent study indicate that the aberrant glycosylation could be a result of initial oncogenic 
phenomena, as well a key event for the induction of invasion and metastasis. 
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Fig. 6. Glycosylation defining malignancy (invasive and metastatic phenotype of tumors) (from [27]). 
Tumor cell malignancy is defined by several key phenotypes: apoptosis (route 1), motility (routes 2 and 5), 
EGF receptor tyrosine kinase (route 3), angiogenesis (routes4and6b), matriptase (matrix-
destroyingenzyme)activity (route 6a), self-adhesion (through cadherin) (route 7a), adhesion to ECM 
(through integrin), adhesion to ECs and platelets (through E- or P-selectin) (route 8), adhesion to blood 
cells and other parenchymatous cells (through siglecs) (route 9). Each phenotype is up- or down-regulated 
by different status of glycosylation. Phenotypes with 1 or 2 and green color inhibit tumor invasiveness. 
Those with 1 or 2 and pink color promote invasiveness. Glycosyl epitopes capable of binding to specific 
ligands (pink color without arrow) promote invasiveness. Ligands with yellow color have variable or unclear 
effect on invasiveness.  
 
Another important point of discussion regard the promotion or inhibition of the tumor 
progression depending on the glycosylation. It has been demonstrated that high expression of 
some glycosyl epitopes leads to a promotion of invasion of metastasis (i.e. β6GlcNAc branching in 
N-linked structure; sialyl-Tn in O-linked structure; sialyl-Lex, sialyl-Lea, and Ley in either N-linked, O-
linked, or lipid-linked structure; GM2, GD3, and sialyl-Gb5 in lipid-linked structure) while expression 
of other epitopes leads to an inhibition of tumor malignancy (β4GlcNAc, competitive with 
β6GlcNAc; histo-blood group A and B competitive with sialylated structures including sialyl- Lex 
and sialyl-Lea; Gb5 competitive with sialyl-Gb5) (Figure 6). 
Very little is known about the mechanism of these glycosyl epitopes related to the expression of 
the respective glycosyltransferase genes, and how this epitopes are able to induces invasive and 
metastatic phenotypes in tumor cells. 
                                                                                                               Sphingolipids glycohydrolases during tumor irradiation 
138 
 
However for some glycohydroles we have an important information and confirmations on their 
mechanisms of action in defining the cancer malignancy.  
In particular, a specific role for sialidase Neu3 has been proposed in intestinal and prostatic tumor 
cells resistant to therapy. These cells express higher quantity of Neu3 with respect to those 
belonging to the tissue around the tumor. Neu3 hydrolizes the PM ganglioside GM3, maintaining 
high the PM LacCer level. LacCer has been shown to act as anti-apoptotic compound, thought the 
increased Bcl-2 and decrease of caspase expression, and this is believed to be a system devised by 
the tumor to escape apoptosis and to proliferate [36,63]. 
On the other hand, the SM is one of the main SL component of the PM, and the production of 
pro-apoptotic Cer by SM hydrolysis by activation of SMases, has been reported to participated to 
the tumor reduction upon treatment of with ionizing radiations. 
 
EFFECT of IONIZING RADIATION  
Radiotherapy represents the therapeutic strategy for the treatment of an increasing number of 
tumors. Recently various schemes of radical radiation therapy, based on the excellent results of 
phase I-II study using the hypofractionation in different cancer diseases, have been developed. 
Thanks to the application of conformal/intensity-modulated techniques in combination with 
precise Image-guided localization of the target, radiotherapy dose escalation has been shown to 
improve disease control. Therefore, it should be possible to use a larger dose per fraction without 
increasing the risk of serious late injury to the normal tissues. In the last years, studies of 
radiobiology focused to provide rationale for evaluating proteins known to play an important role 
in the control of the apoptotic pathway as potential biomarkers. Despite some limitations, such as 
time-consuming procedures, low resolution due to heterogeneity of proteins and post-
translational modifications, proteomic approach could be used to study molecular biomarkers to 
predict and follow the radiotherapy response. 
Irradiation of cancer cells leads to cell death by different mechanisms as summarized in Figure 7 
(extracted from [26]). DNA damage (1), mitochondrial damage (2) and superoxide production (3) 
bring mainly to necrosis, whereas it has been demonstrated that also Cer is involved in cell death 
after irradiation via the induction of apoptosis (4) 
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Fig. 8 Up-regulation of the cell surface associated enzymes involved in SLs
irradiation. 
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The aim of this study is to understand the role played by the SL glycohydrolases in the production 
of Cer in order to develop, by in vitro studies, therapeutic strategies that combine radiotherapy 
with different approaches. These findings could allow the modulation of the cell surface 
associated glycohydrolases and/or the cell surface glycoconjugate composition. 
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MATERIALS 
Commercial chemicals were of the highest purity available, common solvents were distilled 
before use and water was doubly distilled in a glass apparatus. Trypsin, KCl, Trypan blue, reagents 
for cell culture were from Sigma Chemical Co. (St Louis, MO, USA). MEM, DMEM and RPMI-1640  
as well as fetal calf serum (FCS) were purchased from EuroClone (Leeds, UK); AM-calcein, DMEM-
F12 were from Invitrogen (Carlsbad, CA, USA). 6-hexadecanoylamino-4-methylumbelliferone (H-
MUB) 4-methylumbelliferone (MUB), 4-methylumbelliferyl-β-D-galactopyranoside (MUB-Gal) and 
4-methylumbelliferyl-β-D-glucopyranoside (MUB-Glc) were from Glycosynth (Warrington, UK).  
6-hexadecanoylamino-4-methylumbelliferyl-phosphorylcholine (H-MUB-PC) was from Moscerdam 
Substrates (Oegstgeest, Netherland). Hoechst 33258 (2'-[4-ethoxyphenyl]-5-[4-methyl-1-
piperazinyl]-2,5'-bi-1H-benzimidazole trihydrochloride trihydrate) was from Thermo Scientific 
(Rockford, IL, USA). High-performance silica gel thin-layer plates (HPTLC Kieselgel 60) were from 
Merck GmbH (Milan, Italy). 
The preparation of isotopically labeled [3-3H(sphingosine)]GM3 (specific radioactivity, 2.3 
Ci/mmole) and of [1-3H]sphingosine (specific radioactivity, 2.2 Ci/mmole) has been described in 
detail [65].  
Human normal and pathological fibroblasts were prepared as described [66]. Pathological cells 
were prepared from a 7 year old Niemann-Pick type A patient (NPD). These cells had an acidic 
SMase activity on the artificial substrate H-MUB-PC lower than 9% of the activity present in normal 
human fibroblasts and a six fold increase of sphingomyelin content [67]. Tumor cell line T47D 
from breast tumor, HT29 and CaCO2 from colon carcinoma, SHSY-5Y from neuroblastoma tumor; 
A2780, A2780/HPR and A2780/Cis from ovary tumor [68-70] were available in the laboratory. 
 
METHODS 
Cell Cultures 
CaCO2 were cultured and propagated in MEM; A2780 and T47D in RPMI-1640. All of the cultures 
medium were supplemented with 10% FCS (heat-inactivated for all cell lines except fibroblasts), 1% 
glutamine, 1% penicillin/streptomycin. The cells were cultivated as monolayer in a humidified 
atmosphere at 37°C and 5% CO2. 
 
Irradiation of cells 
The most widely used technique for mathematically modeling the effect of radiation on cancer 
cell survival, is linear quadratic (LQ) formalism. The core formula involved is an expression which 
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correlate the probability of survival, S, of a population of mammalian cells following exposure to 
an individual radiation dose, d, as follows: 
S= exp[-αD-βD2] 
where α and β are tumor- or normal tissue-specific parameters. Rearrangement of the equation to 
account for the total impact of n individual fractions of radiation exposure yields another 
common expression for the biologically effective dose (BED):  
BED=nd(1+/α/β) 
The units of BED are Gray (Gy), the standard unit of radiation dose. The BED is a convenient metric 
for comparing the relative impact of a given schedule of radiation dose on a given tumor or tissue, 
as long as the α/β ratio is known or closely estimated. The usual value for tumors is approximately 
10 Gy, but intraoperative methods for delivering hypofractionated partial breast irradiation 
suggested that single doses of up to 21 Gy were tolerated for small tumors (≤2.5 cm) with 
excellent results regarding tumor control. In this study, preliminary experiments allowed to 
increase this dose without a very acute toxicity effect on the mammalian cells irradiated. We 
irradiated the cell lines with 6 Mev photons (direct field) with a linear accelerator. We utilized a 
dose escalation scheme delivering four dose of 10 Gy, 20 Gy, 40 Gy and 60 Gy, with enzymatic 
activity evaluated after every fraction (from 10 min to 48 hr after irradiation). The same enzymatic 
analysis was performed simultaneously on non- irradiated cells.  
 
Determination of cell viability and apoptosis 
At the end of the enzyme assays and at different time after irradiation cell viability was assessed 
by calcein staining and by Trypan blue exclusion [42], whereas cell apoptosis was determined by 
Hoechst 33258 fluorescent staining. For the calcein staining, cells were washed with PBS, the 
plate was then put on ice and 200 µl of a calcein-AM solution (6.25 µg/ml in PBS) were added to 
each well. Cells were incubated for 15 minutes at 37°C, 5% CO2. Calcein-AM was then removed and 
100 µl of PBS and 50 µl of 1% Triton X-100 were added to each well. Plate was stirred at RT for 15 
minutes and then the fluorescence was detected by a microplate reader (Victor, Perkin-Elmer). 
The number of living and dead cells has been determined by counting cells after Trypan blue 
staining, as previously described [71].  
For the detections of  apoptosis, control and irradiated cells were stained with a PBS solution 
containing 10 µg/ml of Hoechst 33258 at room temperature for 10 minutes in the dark and then 
cells were washed three times with PBS and analyzed by fluorescence microscope. Due to the 
chemical properties of the Hoechst 33258 in the condition mentioned above, only the apoptotic 
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cells show the nuclear staining [72]. This was confirmed by the evaluations of the changes of 
nuclear chromatin morphology. A minimum of 700 cells were scored for the incidence of 
chromatin apoptotic changes (condensation, compaction along the periphery of the nucleus and 
segmentations) as previously described [73].  
 
Plasma Membrane (PM) associated hydrolase assays 
We recently described a simple method [42], that allows to measure the activity of several 
glycohydrolases associated with the PMs of intact living cells. This method is based on the 
observation that the fluorogenic substrates commonly used for the in vitro assay of 
glycohydrolase activity (i.e., MUB-Glc, MUB-Gal) are not taken up by living cells [50]. In fact, under 
the appropriate experimental conditions, we did not observe any fluorescence associated with 
the cells. Moreover, the artificial substrates were not subjected to spontaneous, non-enzymatic 
hydrolysis nor hydrolyzed in observable entity by secreted enzymes. Thus, their hydrolysis under 
these experimental conditions is due exclusively to the PM associated enzymatic activities 
[30,42]. 
PM associated β-galactosidase (β-Gal-ase), β-glucosidase (β-Glc-ase) and SMase activities were 
determined in control or irradiated living cells plated in 96-well microplate at the density of 33X103 
cells/cm2 by a high throughput assay (HTA). The β-Gal-ase and β-Glc-ase activities were assayed 
using the artificial substrates MUB-Gal and MUB-Glc solubilized in DMEM-F12 without phenol red 
at pH 6 at the final concentrations of 250 µM and 6 mM respectively. The SM-ase activity was 
assayed using the artificial substrates H-MUB-PC solubilized in the same DMEM-F12 reported for 
the other enzymes at the final concentration of 100 µM. At different times (from 30 min to 2 
hours) aliquots of the medium were analyzed by fluorimetry in a microplate reader (MUB: λex: 355 
nm /λem: 460nm ; H-MUB: λex:405 nm /λem:460nm ) after adding 15 volumes of 0.25 M glycine 
(containing 0,3% Triton X-100 for SM-ase assay), pH 10.7. MUB and H-MUB were used to establish 
the calibration curve in order to quantify the substrates hydrolysis.  
Control experiments were performed also in irradiated cells in order to exclude any activity 
released from lysosomes and/or from other intracellular sites. To this purpose, each enzymatic 
assay was performed on aliquots of medium previously maintained in contact with cells for 
different times. Moreover, to exclude any intracellular enzymatic degradation of the fluorigenic 
substrates, the absence of fluorescence associated with the cells was evaluated at the end of 
each enzymatic assay by fluorescent microscopy and by fluorimetric analysis of the lysed cells in 
0.25 M glycine (pH 10.7) [30,42].  
Activity of PM sialidase Neu3 was determined on the total homogenate using 6 μM [3-
3H(sphingosine)]GM3 as a substrate in the presence of detergent Triton X-100 [13]. This 
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experimental condition strongly reduced the activity of the other sialidases [74]. The enzymatic 
reaction was stopped by adding chloroform/ methanol (2:1 by vol) and the reaction mixture was 
analyzed by HPTLC using the solvent system chloroform/methanol/0.2% aqueous CaCl2, 55:45:10 by 
vol. After chromatography, the separated radioactive lipids were detected and quantified by 
radioactivity imaging performed with a Beta-Imager 2000 instrument (Biospace, Paris, France), 
and the radioactivity associated with individual lipids was determined with the specific β-Vision 
software provided by Biospace.  
 
Cell treatments with tritiated lipids 
Treatment of cell cultures with [1-3H]sphingosine. [1-3H]sphingosine was administered to 20, 
40 and 60 Gy irradiated and control T47D cells in order to metabolically label all SLs as previously 
described [75]. [1-3H]sphingosine dissolved in methanol was transferred into a sterile glass tube, 
and dried under a nitrogen stream; the residue was then solubilized in an appropriate volume of 
pre-warmed (37°C) cell medium to obtain the desired final concentration (3x10-9 M). After a 2 hour 
incubation (pulse), the medium was removed, cells were washed and incubated up to 72 hr (chase) 
with cell medium not containing radioactive precursor. After chase the cells were collected and 
radioactive lipids were analyzed as described below. 
Treatment of cell cultures with [3-3H(sphingosine)] GM3. Isotopically labeled [3-
3H(sphingosine)]. GM3 was administered to both T47D control and irradiated cells (40 Gy dose) 
after 24, 48 and 72 hours from irradiation. [3-3H(sphingosine)]GM3 dissolved in propan-1-ol/water, 
7:3 (v/v), was transferred into a sterile tube and dried under a nitrogen stream. The residue 
solubilised in the cell culture medium without serum at the final concentration of 4.5x10-6 M. In 
order to follow both the lysosomal and PM metabolism of the gangliosides a part of the cells 
were pre-incubated with 50 µM chloroquine for 30 minutes in complete cell cultures medium in 
agreement with previously reported protocol [13]. After removal of the medium and rapid 
washing of cells, 1 ml of the medium containing the radioactive lipid were added to each dish and 
the cells were incubated at 37°C in the presence or not of 50 µM chloroquine for 4 hr. At the end 
of incubation, cells were washed fourth times with complete cell culture medium and then 
collected with PBS.  
 
Radioactive lipid analyses 
Cells were lyophilized and subjected to lipid extraction and SL analyses. Total lipids from 
lyophilised cells were extracted with chloroform/methanol/water 20:10:1 by vol, followed by 
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chloroform/methanol 2:1 by vol. The total lipid extracts were subjected to a two-phase 
partitioning by adding 20% water to the lipid extract; the total lipid extract, the aqueous and 
organic phases were analysed by HPTLC (1000 dpm/lane). [3H]SLs of total extracts and organic 
phases were separated using the solvent system chloroform-methanol-water 110:40:6 by vol, and 
those of aqueous phases with chloroform-methanol-0.2% aqueous CaCl2, 50:42:11 by vol. For the 
specific determination of the Cer content the radioactive lipids of the organic phases were 
separated using the solvent system hexane-chloroform-acetone-acetic acid 20:70:20:2 by vol. 
[3H]SLs were identified by referring to the position of standards in the chromatogram and 
quantified by radioimaging after 48-96 hours of acquisition (β-Imager 2000, Biospace, Paris, 
France).  
 
Statistics 
All the experiments have been performed in fivefold and repeated three times. Data are 
presented as the mean values ± standard deviations and were tested for significance employing 
ONE or Two way ANOVA with Bonferroni post-test analysis, as specified in figure legend. The level 
of significance was set at p<0.05.  
 
Other analytical methods 
The radioactivity associated with lipid extracts was determined by liquid scintillation counting. 
The protein assays were carried out using the DC Protein Assay kit (Biorad). 
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Here it is reported the first detailed in
glycosidases in normal and pathological cells subjected to irradiation, an event accompanied by 
the  production of PM Cer and the onset of apoptotic cell death [76]. 
 
i. PM glicohydrolases activity
Three cell lines (T47D cells from breast cancer, CaCO2 from colon carcinoma, and A2780 from 
ovary tumor) were analyzed for the presence of β
associated to the PM. The PM enzyme activities were determined in living
that excluded contamination from intracellular activity.
As reported in Table 1, all of the tested cells showed a characteristic basal activity of the four 
enzymes to the PM. 
 
Table 1 Specific cell surface enzymes activity in non irr
Each value is the mean of three independent experiments 
gucosidase, β-galactosidase and sphingomyelinase activities were determined in living cells on artificial 
substrates. Sialidase Neu3 activity was determined in the cell homogenate on ganglioside GM3. 
Sphingomyelinase activity was determined at pH 6 and i
 
 
ii. Effect of ionizing radiations on cell PM associated activity in tumor cells
Afterwards we analyzed the same tumor cell lines to assess the effect
Gal, sialidase Neu3 and SMase activites associated to the PM.
As show in Figure 8, after 72h from cell irradiation (dose of 20/40/60 Gy) we observed a general 
increase, even if at different level for each cell line tested, with a significant difference for each 
enzyme considerate. 
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Fig. 8 Effect of ionizing radiations on cell PM associated activity in tumor cells. 
20/40/60 Gy on the enzymes 
associated to the cell surface of breast tumor line T47D, of intestinal carcinoma cell lines CaCO2, of ovary 
tumor cell lines A2780. Enzyme activity associated to the plasma membranes was 
cell irradiation and is expressed as increase of activity with respect of non irradiated cells (control cells). 
Basal enzyme activities as reported in Table 1. 
experiments, 3 replicates for each experiment. Two Way ANOVA followed by Bonferroni post
*p<0.0001 versus control cells, + p<0.001 vs the same enzyme in the previous cell line.
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progressively with the dose. Instead the behavior of Neu3 and SMase was somehow different. In 
irradiated cells, both enzymes showed activity about two times higher of that the control cells 
(1.5-2.5 fold for all the treatments) . Nevertheless, the change of activity could not be modified by 
increasing dose of irradiation. 
 
iii. Effect of ionizing radiations on
Cells were irradiated up to 60 Gy and microscopically analyzed by Tripan Blue assay or by calcein
staining. Figure 9 shows that the number of living cells progressively decrease along 96h in 
culture after receiving 20, 40, and 60 
Correspondently, the percent of apoptosis moved from 5% in control cells to 30
after irradiation. These results on cell growth and apoptosis suggest that the maximum effect due 
to irradiation is already obtained at the d
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Fig. 9 Effect of ionizing radiations on cell death. Cells were irradiated with doses of 20, 40 and 60 Gy and 
assayed for cell growth, percent of apoptosis and plasma membrane sphingolipid hydrolases. Panel a, 
number of living cells determined by trypan-blue exclusion assay up to 96 h from cell irradiation. Panel b, 
percent of apoptosis determined at 24, 48 and 72 h from cell irradiation. Data represent the mean ± SD, n = 
2 independent experiments, 3 replicates for each experiment. Two Way and one Way (in separated graph 
not shown) ANOVA followed by Bonferroni post-tests. 
 
iv. Effect of ionizing radiations on Cer production. 
Cell SLs were metabolically labeled with [1-H3]sphingosine, submitted to irradiation, and the 
radioactive lipids analyzed for changes in their content with respect to the control. Figure 10 
shows the tritium-imaging of TLC separation of lipids extracted from irradiated and control T47D, 
CaCO2 and A2780 after metabolic labeled with [1-H3]sphingosine. Clearly, the double band 
corresponding to the Cer (due to the heterogeneity in acyl chains) displays a higher intensity in 
irradiated cells with respect to the control cells. Quantification of the spots showed that Cer 
significant increased. We calculated that the Cer increased up 3 times respect to the control after 
72h, independently from the radiation dose. No significant differences were detected for other 
SLs between irradiated and control cells (data not shown), suggesting that the majority of this 
Cer is produced in lysosome. 
 
v. Effect of ionizing radiations on Cer production at the PM level. 
To better understand the role played by the SLs glycohydrolases in the production of Cer at the 
PM level after irradiation-dependent activation, T47D cells were subjected to irradiation (40 Gy) in 
normal condition or in conditions that block lysosomal activities (50 µM chloroquine) and then 
metabolic labelled with [3H]GM3.  
After a pulse with radioactive GM3, total lipids were extracted and analyzed for radioactivity 
content after TLC separation. The GM3 administered to the cells is taken up to the cells becoming 
component of PM. In the absence of chloroquine, GM3 enters the cell metabolic pathway of SLs 
and reach the lysosomes by membrane endocytosis. Under these conditions we found, in addition 
to a relatively large amount of unmetabolized GM3, LacCer, GlcCer, and Cer as catabolic products. 
We found also radioactive sphingomyelin, due to the recycling of sphingosine. This latter result is 
the proof that GM3 reached the lysosomes. Cells subjected to 40 Gy irradiation showed a similar 
catabolic pattern and a quantity of Cer 10-35% higher than that of control (Figure 11).  
In the presence of chloroquine, lysosomes are not active and GM3 cannot be intracellularly 
catabolysed. Under these conditions, GM3 was again transformed into LacCer, GlcCer and Cer, but 
                                                                                                    
 
no radioactive sphingomyelin could be observed in the radioactive lipid mixture. This result 
confirms that any change of the GM3 structures occurs at the cell surface, likely by sequen
activity of sialidase Neu3, β-
irradiation, reaching 200% after 72h irradiation. The increase of the cell Cer content in irradiated 
cells was followed by a significant reduction of 
in fibroblasts [13] indicating that Cer is produced also at the PM and that its quantity depends by 
the activity of PM hydrolases. 
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Fig. 10 Metabolic tritium labeling
irradiation up to 20/40/60 Gy. Panel A,
extracted from cells tritium labeled and subjected to irradiation. Extraction was performed 48/72 hr from 
irradiation. Total extract was separ
chloroform-acetone-acetic acid 20:70:20:2 by volume optimal for the ceramide separation. 1000 dpm were 
applied in each line and after separation submitted to 3 day counting for digital rad
radioactivity quantification of ceramide spots reported in panel A (72h); data are expressed as increase of 
radioactivity with respect of non irradiated cells. 
experiments, 3 replicates for each experiment. Two Way ANOVA followed by Bonferroni post
*p<0.004 versus control cells. 
 
 
 
 
Fig. 11 Administration of isotopically tritium labeled GM3 to breast tumor cells T47D.
in culture in the presence of chloroquine 
(sphingosine)]GM3 in the absence of serum. After a short pulse and irradiation with a dose of 40 Gy, the 
radioactive lipids were extracted and separated by TLC. Separation was carried out using the so
system chloroform: methanol:water, 110:40:6 by vol. After TLC separation and radio
quantified for radioactivity content.Data represent the mean ± SD, 
replicates for each experiment. Two Way ANOVA fo
control cells. 
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ated on HPTLC silica gel 100 plates using the solvent system hexane
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SLs hydrolases are known from long time as lysosomal catabolic enzymes necessary to remove 
the hydrophilic head from SLs yielding Cer. Cer is then hydrolyzed by ceramidase to sphingosine 
that can be recycled or completely catabolysed,  outside of lysosomes, to water and carbon 
dioxide [77].  
In recent years a more detailed information became available on the association of some SL 
hydrolases to the PMs [78]. The availability of a simple methodology capable to measure the 
enzyme activities associated with PM in living cells, with no interference of the lysosomal 
activities, allowed to better understand the behavior of these enzymes [42]. Some of these 
enzymes become PM  components as a consequence of  fusion processes between lysosomes 
and PM, but some have a structure different from that of the lysosomal enzymes as for 
glucocerebrosidase GBA2, sialidase Neu3 and probably the neutral SMase [78]. The action of 
these enzymes to modifying the SL structure has been considered a system to modify the PM 
organization and properties, mainly related to the cell signaling processes [79]. An increase of 
activity of PM SMase is claimed to be responsible for the formation of large Cer-rich platforms 
instrumental for the cell signaling [80]. Activation of SMase by TNF-α leads to the Cer dependent 
phosphorylation cascade ending with cell apoptosis [81]. Activation of the PM SMase by the 
ionizing radiations used for radiotherapy of tumors, is well described to participate to the cell 
death and tumor reduction, through cell apoptosis caused  by an increase of PM Cer [64,73]. 
Previously it has been showed that in human fibroblasts an increased expression of sialidase Neu3 
was associated  with an increase of activity of β-glucosidase and β-galactosidase, resulting in an 
increase of PM Cer and cell death by apoptosis [13].  
Here we reported data on the behavior of PM glycosidases in cells treated with ionizing 
radiations, and present the first information on their possible participation to Cer production and 
cell death in radiotherapy treatments. 
We treated several cell lines from breast, ovary, colon and neuroblastoma tumors. All of the cells 
showed basal PM activities of sialidase Neu3, β-Glc, β-Gal and SMase (table 1) that increased after 
cell irradiation. Nevertheless, the quantitative changes of these activities were different in the cell  
lines as reported in Figure 8.  
A tremendous increase of activity of β-Glc and β-Gal was observed after treatment. The activity 
increased with the radiation dose and with time after the treatment. Neu3 and SMase reached 
the maximum value already at 20 Gy to remain then constant up to 60 Gy. Cells, at different dose 
or time from the treatment showed a similar mortality and similar percentage of apoptotic cells. 
This suggest that over a certain increase of dose and time from the treatment, the role of PM 
hydrolase activities, become less relevant. As described for the SM pathway, these signaling 
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mechanisms may be distinct  from the p53-dependent apoptosis. Remarkably, the T47D cell line is 
characterized by high expression levels of mutant p53 [82]. 
To proof that, in parallel with an increase of the glycohydrolase activities, more Cer is actually 
produced in the PM, we administered isotopically tritiated lipids to tumor cells and we followed 
the fate of radioactivity under different experimental conditions. We first administered tritiated 
sphingosine in order to metabolically label all SLs, so that we could follow changes of the 
radioactive SL pattern after cell irradiation. These changes were originated by changes of all the 
cell SL metabolic enzymes, including lysosomal hydrolases whose activities are much higher of 
those associated with the PM. The radioactive pattern displayed changes mainly related to the 
content of neutral glycolipids, with the exception of Cer that triplicated in quantity. This suggests 
that SL hydrolases are probably activated by the ionizing radiations, but does not exclude an up-
regulations of the CERs enzymes, as previously described [83,84]. To better understand the site 
and mechanism of Cer production in irradiated cells, tritiated GM3 was administered to T47D 
breast cancer cells. Our idea was to follow the production of PM Cer, due to the sequential 
activities of Neu3, β-Gal and β-Glc, under conditions that block lysosomal activity. To avoid 
lysosomal catabolism, we administered GM3 in the presence of chloroquine, a well known 
inhibitor of lysosomal activity, and followed its metabolic fate. In the absence of chloroquine, we 
observed a minor but statistically significant increase of Cer. The experimental conditions used, 
that privileged the permanence of administered ganglioside at the PM with respect to the 
intracellular localization and the high dilution of radioactive Cer deriving from the catabolism of 
exogenously administered ganglioside into non radioactive endogenous Cer, does not allow to 
overlap the result obtained by steady-state metabolic labeling of all SLs with tritiated sphingosine. 
In the presence of chloroquine, we had an high increase of Cer. We calculated that the absolute 
quantitative increase of Cer determined in the presence of chloroquine corresponds to the minor 
increase of total cell Cer in the absence of chloroquine. This suggests that under our experimental 
conditions, the Cer formed in lysosomes is rapidly catabolysed to sphingosine and that the 
observed increase of Cer is largely due to the production of a more time existing PM Cer. 
The increase of PM Cer in cells subjected to ionizing radiations was shown to participate to the 
onset of cell death [85]. The activation of SMase has been regarded as the main mechanism for 
the production of pro-apoptotic Cer. The information presented in this paper that  ionizing 
radiations also activate PM glycohydrolases suggests that PM Cer can derive by all PM SLs. This 
requires additional care for developing radiotherapy protocols. As reported in Figure 2, tumor 
cells show different patterns of enzyme activities. Thus, it would be necessary to know which is 
the ratio between LacCer and Cer at the end of irradiation. LacCer is an antiapototic compound 
and it could cancel or reduce the apoptotic effect of Cer.  
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The involvement of glycosidases in PM Cer production increases several times the number of 
enzymes that can participate to induce cell apoptosis and adds a new knowledge on the 
apoptotic mediated cell death induced by ionizing irradiations. We summarized this in Figure 6. 
The fact that PM glycosidases can participate to the induction of apoptosis in tumor cells open 
the possibility to design drugs capable to modulate their activity. This would allow to develop 
new chemotherapy treatments in combination with radiotherapy. Moreover the actions of the 
cell surface associated glycosidases are not confined to the GSLs metabolism but also to other cell 
surface associated glycoconjugates. Their modifications during the cell irradiation need to be 
further study in the future. 
 
 
 
 
 
Fig. 12 Simplified scheme of the effects of ionizing radiations on cells in culture (from [76]) 
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